

Supporting Information

Synthesis of Structurally Diverse Pyrazolo[1,2-*a*]pyrazolones Based on Selective C–H Bond Alkenylation-Annulation of 1-Arylpyrazolidinones with Allenyl Acetates

Yongdi Xin^a, Qianting Zhou^a, Bin Li^a, Biao Cheng,^b Xinying Zhang^{a,*}, Xuesen Fan^{a,*}

^a*State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China*

^b*College of Tobacco Science, Henan Agricultural University, Zhengzhou 450046, China*

Table of Contents

I	General experimental information	S3
II	Experimental procedures and spectroscopic data	S4-S34
III	Mechanistic studies	S35-S38
IV	References	S39
V	NMR spectra of 3a-3ee	S40-S77
VI	NMR spectra of 4a-4t	S78-S103
VII	NMR spectra of 5a-5d	S104-S107
VIII	NMR spectra of 6a-6e	S108-S112
IX	NMR spectra of 7a-7e	S113-S117
X	NMR spectra of 8-9	S118-S120
XI	X-ray crystal structure and data for 3d	S121-S122

I. General experimental information

Commercial reagents were used without further purification. 1-Arylpyrazolidinones **1**,^[1] allenyl acetates **2**,^[2] and [RhCp*Cl₂]₂^[3] were prepared based on literature procedures. Melting points were recorded with a micro melting point apparatus and uncorrected. The ¹H NMR spectra were recorded at 400 MHz or 600 MHz. The ¹³C NMR spectra were recorded at 100 MHz or 150 MHz. The ¹⁹F NMR spectra were recorded at 565 MHz or 376 MHz. Chemical shifts were expressed in parts per million (δ), and were reported as s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublet), td (triplet of doublets), m (multiplet), etc. The coupling constants J were given in Hz. High resolution mass spectra (HRMS) were obtained via ESI-TOF mode by using a BRUKER compact mass spectrometer. All reactions were monitored by thin layer chromatography (TLC) using silica gel plates (silica gel 60 F254 0.25 mm), and components were visualized by observation under UV light (254 and 365 nm).

II. Experimental procedures and spectroscopic data

1. Typical procedure for the synthesis of **3a** and spectroscopic data of **3a-3ee**

To a reaction tube equipped with a stir bar were charged with 1-phenylpyrazolidin-3-one (**1a**, 64.8 mg, 0.4 mmol), DCE (2 mL), $[\text{RhCp}^*\text{Cl}_2]_2$ (3.1 mg, 0.005 mmol), NaOAc (8.2 mg, 0.1 mmol) and 1-phenylbuta-2,3-dien-1-yl acetate (**2a**, 37.6 mg, 0.2 mmol). The tube was then sealed, and the mixture was stirred at room temperature under argon for 2 h. Upon completion, it was quenched with saturated brine, and extracted with dichloromethane (10 mL \times 3). The combined organic phases were dried over anhydrous Na_2SO_4 , filtered through a pad of celite, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using petroleum ether/ethyl acetate (2:1) as eluent to afford **3a**. **3b-3ee** were obtained in a similar manner.

(*E*)-9-Methyl-9-styryl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (**3a**)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (45.3 mg, 78%), mp 121.6-122.5 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.35 (d, J = 7.2 Hz, 2H), 7.29-7.26 (m, 3H), 7.22-7.19 (m, 1H), 7.14 (d, J = 7.2 Hz, 1H), 7.05 (td, J_1 = 7.2 Hz, J_2 = 1.2 Hz, 1H), 6.79 (d, J = 7.8 Hz, 1H), 6.50 (d, J = 15.6 Hz, 1H), 6.43 (d, J = 15.6 Hz, 1H), 3.88 (td, J_1 = 9.0 Hz, J_2 = 4.8 Hz, 1H), 3.50-3.45 (m, 1H), 3.04-2.98 (m, 1H), 2.82-2.78 (m, 1H), 2.05 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.6, 147.1, 136.2, 134.9, 130.3, 129.3, 128.9, 128.5, 127.9, 126.9, 122.9, 122.7, 110.0, 66.2, 51.2, 35.3, 24.4. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{19}\text{H}_{18}\text{N}_2\text{NaO}$ 313.1311; Found 313.1308.

(*E*)-7,9-Dimethyl-9-styryl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (**3b**)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (42.0 mg, 69%), mp 82.3-89.3 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.30-7.28 (m, 2H), 7.21-7.17 (m, 2H), 7.15-7.10 (m, 1H), 7.00 (dd, J_1 = 8.0 Hz, J_2 = 0.8 Hz, 1H), 6.86 (s, 1H), 6.61 (d, J = 8.0 Hz, 1H), 6.45 (d, J = 16.0 Hz, 1H), 6.34 (d, J = 16.0 Hz, 1H), 3.77 (td, J_1 = 8.4 Hz, J_2 = 4.4 Hz, 1H), 3.38-3.31 (m, 1H), 2.96-2.87 (m, 1H), 2.74-2.67 (m, 1H), 2.26 (s, 3H), 1.96 (s, 3H).

$^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 164.8, 145.0, 136.3, 135.2, 132.7, 130.5, 129.5, 129.2, 128.6, 127.9, 126.9, 123.2, 109.9, 66.3, 51.7, 35.5, 24.5, 21.1. HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{NaO}$ 327.1468; Found 327.1472.

(E)-7-Chloro-9-methyl-9-styryl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3c)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (48.7 mg, 75%), mp 124.0-124.9 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.36 (d, $J = 7.2$ Hz, 2H), 7.28 (t, $J = 7.2$ Hz, 2H), 7.24-7.21 (m, 2H), 7.10 (d, $J = 1.8$ Hz, 1H), 6.70 (d, $J = 8.4$ Hz, 1H), 6.52 (d, $J = 15.6$ Hz, 1H), 6.38 (d, $J = 15.6$ Hz, 1H), 3.84 (td, $J_1 = 8.4$ Hz, $J_2 = 4.2$ Hz 1H), 3.47-3.43 (m, 1H), 3.02-2.96 (m, 1H), 2.82-2.78 (m, 1H), 2.03 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.7, 145.8, 136.8, 136.0, 129.8, 129.7, 129.0, 128.6, 128.1, 128.0, 126.9, 123.0, 111.0, 66.3, 51.1, 35.3, 24.4. HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{19}\text{H}_{17}\text{ClN}_2\text{NaO}$ 347.0922; Found 347.0927.

(E)-7-Bromo-9-methyl-9-styryl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3d)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (49.4 mg, 67%), mp 73.5-74.2 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.38-7.36 (m, 3H), 7.29 (t, $J = 7.2$ Hz, 2H), 7.24-7.21 (m, 2H), 6.66 (d, $J = 8.4$ Hz, 1H), 6.52 (d, $J = 16.2$ Hz, 1H), 6.38 (d, $J = 15.6$ Hz, 1H), 3.85 (td, $J_1 = 9.0$ Hz, $J_2 = 4.8$ Hz, 1H), 3.48-3.44 (m, 1H), 3.02-2.96 (m, 1H), 2.83-2.78 (m, 1H), 2.03 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.6, 146.2, 137.2, 136.0, 131.8, 129.8, 129.7, 128.6, 128.1, 127.0, 125.8, 115.2, 111.5, 66.2, 51.0, 35.3, 24.4. HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{19}\text{H}_{17}\text{BrN}_2\text{NaO}$ 391.0416; Found 391.0406.

(E)-9-Methyl-9-styryl-7-(trifluoromethyl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3e)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (47.0 mg, 66%), mp 104.8-105.6 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.54 (d, $J = 8.4$ Hz, 1H), 7.37-7.36 (m, 3H), 7.29 (t, $J = 7.8$ Hz, 2H), 7.23 (t, $J = 7.2$ Hz, 1H), 6.82 (d, $J = 8.4$ Hz, 1H), 6.53 (d, $J = 15.6$ Hz, 1H), 6.40 (d, $J = 15.6$ Hz, 1H), 3.92 (td, $J_1 = 9.0$ Hz, $J_2 = 4.8$ Hz, 1H), 3.57-3.53 (m, 1H), 3.05-2.99 (m, 1H), 2.86-2.82 (m, 1H), 2.07 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.5, 149.5, 135.8, 135.6, 129.9, 129.4, 128.6, 128.1, 126.9, 126.7 (q, $^3J_{\text{C}-\text{F}} = 3.0$ Hz), 125.0 (q,

$^2J_{C-F} = 32.1$ Hz), 124.3 (q, $^1J_{C-F} = 269.9$ Hz), 119.9 (q, $^3J_{C-F} = 3.3$ Hz), 109.5, 66.2, 50.1, 35.1, 24.3. ^{19}F NMR (565 MHz, $CDCl_3$) δ : -61.30 (s). HRMS (ESI) m/z : [M+Na]⁺ Calcd for $C_{20}H_{17}F_3N_2NaO$ 381.1185; Found 381.1174.

(E)-6,9-Dimethyl-9-styryl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3f)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (54.8 mg, 90%), mp 42.0-43.8 °C. 1H NMR ($CDCl_3$, 600 MHz): δ 7.35 (d, $J = 7.2$ Hz, 2H), 7.28-7.26 (m, 2H), 7.20 (t, $J = 7.2$ Hz, 1H), 7.02 (d, $J = 8.4$ Hz, 1H), 6.87 (d, $J = 7.2$ Hz, 1H), 6.61 (s, 1H), 6.50 (d, $J = 16.2$ Hz, 1H), 6.44 (d, $J = 16.2$ Hz, 1H), 3.86 (td, $J_1 = 8.4$ Hz, $J_2 = 4.8$ Hz, 1H), 3.47-3.43 (m, 1H), 3.02-2.97 (m, 1H), 2.81-2.76 (m, 1H), 2.37 (s, 3H), 2.04 (s, 3H). $^{13}C\{^1H\}$ NMR ($CDCl_3$, 100 MHz): δ 164.6, 147.3, 139.2, 136.3, 132.2, 130.5, 129.1, 128.5, 127.8, 126.9, 123.7, 122.4, 110.7, 66.1, 51.2, 35.4, 24.6, 21.6. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $C_{20}H_{20}N_2NaO$ 327.1468; Found 327.1471.

(E)-6-Chloro-9-methyl-9-styryl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3g)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (50.6 mg, 78%), mp 49.5-50.3 °C. 1H NMR ($CDCl_3$, 600 MHz): δ 7.35 (d, $J = 7.2$ Hz, 2H), 7.27 (t, $J = 7.8$ Hz, 2H), 7.21 (t, $J = 7.2$ Hz, 1H), 7.04 (d, $J = 8.4$ Hz, 1H), 7.00 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.2$ Hz, 1H), 6.76 (d, $J = 1.8$ Hz, 1H), 6.48 (d, $J = 15.6$ Hz, 1H), 6.40 (d, $J = 16.2$ Hz, 1H), 3.85 (td, $J_1 = 9.0$ Hz, $J_2 = 4.8$ Hz, 1H), 3.50-3.46 (m, 1H), 3.01-2.96 (m, 1H), 2.83-2.78 (m, 1H), 2.02 (s, 3H). $^{13}C\{^1H\}$ NMR ($CDCl_3$, 100 MHz): δ 164.5, 148.2, 136.0, 134.7, 133.4, 129.8, 129.6, 128.6, 128.0, 126.9, 123.6, 122.8, 110.3, 66.0, 50.6, 35.2, 24.4. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $C_{19}H_{17}ClN_2NaO$ 347.0922; Found 347.0909.

(E)-6-Bromo-9-methyl-9-styryl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3h)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (58.0 mg, 79%), mp 45.3-46.3 °C. 1H NMR ($CDCl_3$, 600 MHz): δ 7.34 (d, $J = 7.8$ Hz, 2H), 7.27 (t, $J = 7.2$ Hz, 2H), 7.21 (t, $J = 7.2$ Hz, 1H), 7.15 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.8$ Hz, 1H), 6.97 (d, $J = 7.8$ Hz, 1H), 6.91 (d, $J = 1.2$ Hz, 1H), 6.48 (d, $J = 15.6$ Hz, 1H), 6.40 (d, $J = 15.6$

Hz, 1H), 3.84 (td, J_1 = 8.4 Hz, J_2 = 4.8 Hz, 1H), 3.49-3.45 (m, 1H), 3.01-2.95 (m, 1H), 2.82-2.77 (m, 1H), 2.02 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.5, 148.4, 136.0, 134.0, 129.70, 129.67, 128.6, 128.1, 126.9, 125.7, 124.0, 122.5, 113.2, 66.1, 50.7, 35.2, 24.4. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{19}\text{H}_{17}\text{BrN}_2\text{NaO}$ 391.0416; Found 391.0428.

(E)-5-Fluoro-9-methyl-9-styryl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3i)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (31.0 mg, 50%), mp 57.4-58.3 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.36-7.34 (m, 2H), 7.29-7.26 (m, 2H), 7.23-7.20 (m, 1H), 7.02-6.98 (m, 2H), 6.94-6.92 (m, 1H), 6.51 (d, J = 15.6 Hz, 1H), 6.41 (d, J = 16.2 Hz, 1H), 4.03-3.99 (m, 1H), 3.64-3.60 (m, 1H), 3.03-2.97 (m, 1H), 2.82-2.77 (m, 1H), 2.06 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.9, 149.0 (d, $^1J_{\text{C-F}} = 244.2$ Hz), 138.3 (d, $^3J_{\text{C-F}} = 3.5$ Hz), 136.0, 134.0 (d, $^2J_{\text{C-F}} = 13.4$ Hz), 129.8, 129.6, 128.5, 128.0, 126.9, 124.1 (d, $^3J_{\text{C-F}} = 5.6$ Hz), 118.3 (d, $^4J_{\text{C-F}} = 3.3$ Hz), 115.8 (d, $^2J_{\text{C-F}} = 18.2$ Hz), 66.7, 52.1 (d, $^4J_{\text{C-F}} = 2.1$ Hz), 35.6, 24.6. ^{19}F NMR (565 MHz, CDCl_3) δ : -132.78 – -132.81 (m). HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{19}\text{H}_{17}\text{FN}_2\text{NaO}$ 331.1217; Found 331.1203.

(E)-5-Methoxy-9-methyl-9-styryl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3j)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (40.8 mg, 64%), mp 73.9-74.9 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.35 (d, J = 7.2 Hz, 2H), 7.27 (t, J = 7.2 Hz, 2H), 7.22-7.18 (m, 1H), 7.04 (t, J = 7.6 Hz, 1H), 6.82 (d, J = 8.4 Hz, 1H), 6.77 (d, J = 7.6 Hz, 1H), 6.52 (d, J = 16.0 Hz, 1H), 6.43 (d, J = 16.0 Hz, 1H), 4.02 (td, J_1 = 8.4 Hz, J_2 = 4.4 Hz, 1H), 3.87 (s, 3H), 3.59-3.52 (m, 1H), 3.01-2.92 (m, 1H), 2.78-2.71 (m, 1H), 2.05 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 165.2, 146.4, 136.32, 136.26, 135.2, 130.4, 129.2, 128.5, 127.8, 126.8, 124.3, 114.8, 110.8, 66.5, 55.7, 53.0, 35.7, 24.7. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{NaO}_2$ 343.1417; Found 343.1420.

(E)-6,7,9-Trimethyl-9-styryl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3k)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (57.4 mg, 90%), mp 136.9-137.7 °C. ¹H NMR (CDCl₃, 600 MHz): δ 7.36-7.35 (m, 2H), 7.27-7.25 (m, 2H), 7.21-7.18 (m, 1H), 6.89 (s, 1H), 6.60 (s, 1H), 6.51 (d, *J* = 16.2 Hz, 1H), 6.42 (d, *J* = 15.6 Hz, 1H), 3.83 (td, *J*₁ = 8.4 Hz, *J*₂ = 4.8 Hz, 1H), 3.43-3.39 (m, 1H), 3.01-2.95 (m, 1H), 2.80-2.75 (m, 1H), 2.26 (s, 3H), 2.24 (s, 3H), 2.03 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 164.7, 145.4, 137.5, 136.4, 132.5, 131.3, 130.6, 129.0, 128.5, 127.8, 126.9, 123.5, 111.4, 66.2, 51.8, 35.5, 24.6, 20.3, 19.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₂₂N₂NaO 341.1624; Found 341.1621.

(E)-2,2,9-Trimethyl-9-styryl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3l)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (34.1 mg, 54%), mp 134.8-135.8 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.35-7.33 (m, 2H), 7.29-7.24 (m, 3H), 7.22-7.18 (m, 1H), 7.15 (d, *J* = 7.2 Hz, 1H), 7.03 (td, *J*₁ = 7.6 Hz, *J*₂ = 0.8 Hz, 1H), 6.76 (d, *J* = 8.0 Hz, 1H), 6.49 (d, *J* = 16.0 Hz, 1H), 6.39 (d, *J* = 16.0 Hz, 1H), 3.66 (d, *J* = 8.4 Hz, 1H), 3.21 (d, *J* = 8.4 Hz, 1H), 2.06 (s, 3H), 1.41 (s, 3H), 1.29 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 170.0, 147.2, 136.4, 135.0, 130.4, 129.1, 128.9, 128.6, 127.9, 127.0, 122.8, 122.6, 110.0, 66.1, 64.1, 46.0, 24.6, 23.3, 22.8. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₂₂N₂NaO⁺ 341.1624; Found 341.1619.

(E)-2,2,7,9-Tetramethyl-9-styryl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3m)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (26.6 mg, 40%), mp 137.5-138.5 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.35-7.33 (m, 2H), 7.28-7.24 (m, 2H), 7.21-7.17 (m, 1H), 7.06-7.04 (m, 1H), 6.93 (s, 1H), 6.66 (d, *J* = 8.0 Hz, 1H), 6.49 (d, *J* = 15.6 Hz, 1H), 6.37 (d, *J* = 15.6 Hz, 1H), 3.62 (d, *J* = 8.4 Hz, 1H), 3.16 (d, *J* = 8.0 Hz, 1H), 2.32 (s, 3H), 2.03 (s, 3H), 1.40 (s, 3H), 1.27 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 170.1, 145.0, 136.5, 135.2, 132.5, 130.5, 129.4, 128.9, 128.6, 127.8, 126.9, 123.1, 109.9, 66.1, 64.6, 46.0, 24.5, 23.3, 22.8, 21.1. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₂₄N₂NaO⁺ 355.1781; Found 355.1787.

(E)-7-Methoxy-2,2,9-trimethyl-9-styryl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3n)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (30.4 mg, 44%), mp 80.8-81.8 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.36-7.34 (m, 2H), 7.29-7.25 (m, 2H), 7.22-7.18 (m, 1H), 6.81 (dd, $J_1 = 8.4$ Hz, $J_2 = 2.4$ Hz, 1H), 6.71-6.69 (m, 2H), 6.51 (d, $J = 15.6$ Hz, 1H), 6.38 (d, $J = 16.0$ Hz, 1H), 3.79 (s, 3H), 3.61 (d, $J = 8.0$ Hz, 1H), 3.14 (d, $J = 8.0$ Hz, 1H), 2.05 (s, 3H), 1.40 (s, 3H), 1.28 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 170.3, 156.3, 141.1, 136.40, 136.35, 130.3, 129.2, 128.6, 127.9, 127.0, 114.2, 110.8, 108.8, 66.3, 65.0, 56.0, 46.0, 24.5, 23.2, 22.7. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{22}\text{H}_{24}\text{N}_2\text{NaO}_2$ 371.1730; Found 371.1734.

(E)-7-Fluoro-2,2,9-trimethyl-9-styryl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3o)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (31.5 mg, 47%), mp 118.2-119.2 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.36-7.34 (m, 2H), 7.30-7.26 (m, 2H), 7.24-7.20 (m, 1H), 6.96 (td, $J_1 = 8.8$ Hz, $J_2 = 2.4$ Hz, 1H), 6.87 (dd, $J_1 = 8.0$ Hz, $J_2 = 2.4$ Hz, 1H), 6.69 (dd, $J_1 = 8.4$ Hz, $J_2 = 4.0$ Hz, 1H), 6.50 (d, $J = 15.6$ Hz, 1H), 6.36 (d, $J = 16.0$ Hz, 1H), 3.62 (d, $J = 8.4$ Hz, 1H), 3.17 (d, $J = 8.0$ Hz, 1H), 2.04 (s, 3H), 1.40 (s, 3H), 1.29 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 170.2, 159.3 (d, $^1J_{\text{C-F}} = 239.5$ Hz), 143.4 (d, $^4J_{\text{C-F}} = 2.2$ Hz), 136.6 (d, $^3J_{\text{C-F}} = 8.5$ Hz), 136.2, 129.8, 129.5, 128.6, 128.0, 127.0, 115.6 (d, $^2J_{\text{C-F}} = 23.9$ Hz), 110.8 (d, $^3J_{\text{C-F}} = 9.2$ Hz), 110.1 (d, $^2J_{\text{C-F}} = 24.7$ Hz), 66.2 (d, $^4J_{\text{C-F}} = 2.2$ Hz), 64.6, 46.0, 24.5, 23.2, 22.7. ^{19}F NMR (376 MHz, CDCl_3): δ -120.49 (td, $J_1 = 7.9$ Hz, $J_2 = 4.1$ Hz). HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{21}\text{H}_{21}\text{FN}_2\text{NaO}^+$ 359.1530; Found 359.1540.

(E)-2,2,9-Trimethyl-9-styryl-7-(trifluoromethyl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3p)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (31.5 mg, 41%), mp 90.7-91.7 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.53 (d, $J = 8.0$ Hz, 1H), 7.37-7.35 (m, 3H), 7.29 (t, $J = 7.2$ Hz, 2H), 7.25-7.21 (m, 1H), 6.80 (d, $J = 8.4$ Hz, 1H), 6.51 (d, $J = 16.0$ Hz, 1H), 6.37 (d, $J = 15.6$ Hz, 1H), 3.69 (d, $J = 8.4$ Hz, 1H), 3.29 (d, $J = 8.4$ Hz, 1H), 2.07 (s, 3H), 1.42 (s, 3H), 1.31 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 170.0, 149.6, 136.0, 135.7, 129.7, 129.5, 128.7, 128.2, 127.0, 126.7 (q, $^3J_{\text{C-F}} = 3.3$ Hz), 124.9 (q, $^2J_{\text{C-F}} = 31.8$ Hz), 124.4 (q, $^1J_{\text{C-F}} =$

269.5 Hz), 119.8 (q, $^3J_{C-F} = 3.4$ Hz), 109.5, 66.1, 63.2, 46.0, 24.5, 23.4. ^{19}F NMR (376 MHz, $CDCl_3$): δ -61.28 (s). HRMS (ESI) m/z : [M+Na]⁺ Calcd for $C_{22}H_{21}F_3N_2NaO^+$ 409.1498; Found 409.1487.

(E)-9-Methyl-9-(4-methylstyryl)-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3q)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (44.5 mg, 73%), mp 44.6-45.2 °C. 1H NMR ($CDCl_3$, 600 MHz): δ 7.28-7.23 (m, 3H), 7.13 (d, $J = 7.2$ Hz, 1H), 7.07 (d, $J = 8.4$ Hz, 2H), 7.04 (td, $J_1 = 7.8$ Hz, $J_2 = 0.6$ Hz, 1H), 6.78 (d, $J = 7.8$ Hz, 1H), 6.46 (d, $J = 16.2$ Hz, 1H), 6.38 (d, $J = 16.2$ Hz, 1H), 3.87 (td, $J_1 = 9.0$ Hz, $J_2 = 4.8$ Hz, 1H), 3.48-3.44 (m, 1H), 3.03-2.97 (m, 1H), 2.82-2.77 (m, 1H), 2.30 (s, 3H), 2.04 (s, 3H). $^{13}C\{^1H\}$ NMR ($CDCl_3$, 150 MHz): δ 164.6, 147.2, 137.8, 135.1, 133.5, 129.3, 129.28, 129.26, 128.9, 126.8, 122.9, 122.8, 110.0, 66.3, 51.2, 35.4, 24.6, 21.3. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $C_{20}H_{20}N_2NaO$ 327.1468; Found 327.1470.

(E)-9-(4-Ethylstyryl)-9-methyl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3r)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow oil (42.6 mg, 67%). 1H NMR ($CDCl_3$, 600 MHz): δ 7.28-7.26 (m, 3H), 7.13 (d, $J = 7.8$ Hz, 1H), 7.11 (d, $J = 7.8$ Hz, 2H), 7.05 (td, $J_1 = 7.8$ Hz, $J_2 = 1.2$ Hz, 1H), 6.78 (d, $J = 7.8$ Hz, 1H), 6.48 (d, $J = 15.6$ Hz, 1H), 6.40 (d, $J = 15.6$ Hz, 1H), 3.87 (td, $J_1 = 8.4$ Hz, $J_2 = 4.2$ Hz, 1H), 3.49-3.45 (m, 1H), 3.03-2.97 (m, 1H), 2.82-2.77 (m, 1H), 2.61 (q, $J = 7.2$ Hz, 2H), 2.05 (s, 3H), 1.20 (t, $J = 7.2$ Hz, 3H). $^{13}C\{^1H\}$ NMR ($CDCl_3$, 150 MHz): δ 164.6, 147.2, 144.2, 135.1, 133.7, 129.4, 129.3, 128.9, 128.1, 126.9, 122.9, 122.8, 110.0, 66.3, 51.2, 35.4, 28.7, 24.6, 15.6. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $C_{21}H_{22}N_2NaO$ 341.1624; Found 341.1632.

(E)-9-(2-([1,1'-Biphenyl]-4-yl)vinyl)-9-methyl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3s)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (40.4 mg, 55%), mp 136.0-136.9 °C. 1H NMR ($CDCl_3$, 400 MHz): δ 7.59-7.57 (m, 2H), 7.52 (d, $J = 8.4$ Hz, 2H), 7.44-7.40 (m, 4H), 7.34-7.25 (m, 2H), 7.16 (d, $J = 7.2$ Hz, 1H), 7.08-7.04 (m, 1H), 6.79 (d, $J = 8.0$ Hz, 1H), 6.55 (d, $J = 16.0$ Hz, 1H), 6.47 (d, $J = 15.6$ Hz, 1H), 3.89 (td, $J_1 = 8.4$ Hz, $J_2 = 4.0$ Hz, 1H), 3.51-3.45 (m, 1H), 3.06-2.97 (m, 1H), 2.84-2.77 (m, 1H), 2.07

(s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 164.7, 147.2, 140.7, 140.6, 135.4, 135.0, 130.5, 129.0, 128.90, 128.88, 127.44, 127.37, 127.3, 127.0, 123.0, 122.8, 110.1, 66.3, 51.3, 35.4, 24.6. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{25}\text{H}_{22}\text{N}_2\text{NaO}$ 389.1624; Found 389.1622.

(E)-9-(4-Fluorostyryl)-9-methyl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3t)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (35.7 mg, 58%), mp 114.8-115.7 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.26-7.19 (m, 3H), 7.06 (d, $J = 7.2$ Hz, 1H), 6.98 (td, $J_1 = 7.6$ Hz, $J_2 = 0.4$ Hz, 1H), 6.91-6.86 (m, 2H), 6.72 (d, $J = 8.0$ Hz, 1H), 6.40 (d, $J = 16.0$ Hz, 1H), 6.28 (d, $J = 16.0$ Hz, 1H), 3.81 (td, $J_1 = 8.8$ Hz, $J_2 = 4.8$ Hz, 1H), 3.44-3.37 (m, 1H), 2.98-2.89 (m, 1H), 2.77-2.69 (m, 1H), 1.97 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.7, 162.6 (d, $^1J_{\text{C-F}} = 245.4$ Hz), 147.2, 134.9, 132.5 (d, $^4J_{\text{C-F}} = 3.0$ Hz), 130.2 (d, $^5J_{\text{C-F}} = 2.4$ Hz), 129.0, 128.5 (d, $^3J_{\text{C-F}} = 7.1$ Hz), 128.2, 123.0, 122.7, 115.5 (d, $^2J_{\text{C-F}} = 21.2$ Hz), 110.1, 66.2, 51.3, 35.4. ^{19}F NMR (565 MHz, CDCl_3): δ -114.10 -- -114.15 (m). HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{19}\text{H}_{17}\text{FN}_2\text{NaO}$ 331.1217; Found 331.1214.

(E)-9-(4-Bromostyryl)-9-methyl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3u)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (55.5 mg, 75%), mp 54.3-55.3 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.39 (d, $J = 8.8$ Hz, 2H), 7.30-7.26 (m, 1H), 7.21 (d, $J = 8.4$ Hz, 2H), 7.14 (d, $J = 7.2$ Hz, 1H), 7.07-7.03 (m, 1H), 6.79 (d, $J = 8.0$ Hz, 1H), 6.47-6.39 (m, 2H), 3.89 (td, $J_1 = 8.8$ Hz, $J_2 = 4.0$ Hz, 1H), 3.51-3.44 (m, 1H), 3.05-2.97 (m, 1H), 2.84-2.76 (m, 1H), 2.05 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 164.8, 147.2, 135.3, 134.7, 131.7, 131.2, 129.1, 128.5, 128.2, 123.1, 122.7, 121.8, 110.1, 66.2, 51.3, 35.4, 24.5. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{19}\text{H}_{17}\text{BrN}_2\text{NaO}$ 391.0416; Found 391.0407.

(E)-9-Methyl-9-(4-(trifluoromethyl)styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3v)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (39.4 mg, 55%), mp 44.3-45.3 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.52 (d, $J = 8.4$ Hz, 2H), 7.45 (d, $J = 8.4$ Hz, 2H), 7.29 (t, $J = 7.8$ Hz, 1H), 7.15 (d, $J = 7.2$ Hz, 1H), 7.06 (t, $J = 7.2$ Hz, 1H), 6.80 (d, $J = 7.8$ Hz, 1H), 6.55 (d, $J = 15.6$ Hz, 1H), 6.51 (d, $J = 16.2$ Hz, 1H),

3.90 (td, J_1 = 8.4 Hz, J_2 = 4.2 Hz, 1H), 3.51-3.46 (m, 1H), 3.05-2.99 (m, 1H), 2.84-2.79 (m, 1H), 2.07 (s, 3H).

$^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.9, 147.2, 139.9, 134.5, 133.0, 129.7 (q, $^2J_{\text{C-F}} = 31.7$ Hz), 129.2,

128.0, 127.1, 125.5 (q, $^3J_{\text{C-F}} = 3.5$ Hz), 124.3 (q, $^1J_{\text{C-F}} = 270.5$ Hz), 123.1, 122.6, 110.2, 66.2, 51.3, 35.4, 24.4.

^{19}F NMR (565 MHz, CDCl_3): δ -62.50 (s). HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{20}\text{H}_{17}\text{F}_3\text{N}_2\text{NaO}$ 381.1185;

Found 381.1177.

(E)-9-Methyl-9-(3-methylstyryl)-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3w)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow oil (41.4 mg, 68%). ^1H NMR (CDCl_3 , 600 MHz): δ

7.28-7.25 (m, 1H), 7.18 (s, 1H), 7.17-7.13 (m, 3H), 7.05-7.01 (m, 2H), 6.78 (d, $J = 7.8$ Hz, 1H), 6.47 (d, $J =$

16.2 Hz, 1H), 6.42 (d, $J = 15.6$ Hz, 1H), 3.86 (td, J_1 = 8.4 Hz, J_2 = 4.2 Hz, 1H), 3.49-3.44 (m, 1H), 3.02-2.96

(m, 1H), 2.82-2.77 (m, 1H), 2.30 (s, 3H), 2.05 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.6, 147.2,

138.1, 136.2, 135.0, 130.1, 129.4, 128.9, 128.7, 128.5, 127.5, 124.2, 122.9, 122.7, 110.0, 66.3, 51.2, 35.4, 24.5,

21.4. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{NaO}$ 327.1468; Found 327.1479.

(E)-9-(3-Chlorostyryl)-9-methyl-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3x)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (45.2 mg, 70%), mp 45.6-46.2 °C. ^1H NMR (CDCl_3 ,

400 MHz): δ 7.35 (s, 1H), 7.30-7.26 (m, 1H), 7.23-7.16 (m, 3H), 7.14-7.13 (m, 1H), 7.05 (td, J_1 = 7.2 Hz, J_2 =

0.8 Hz, 1H), 6.79 (d, $J = 8.0$ Hz, 1H), 6.49-6.40 (m, 2H), 3.89 (td, J_1 = 8.4 Hz, J_2 = 4.4 Hz, 1H), 3.51-3.44 (m,

1H), 3.05-2.97 (m, 1H), 2.84-2.77 (m, 1H), 2.05 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.8, 147.2,

138.2, 134.7, 134.5, 131.9, 129.8, 129.1, 128.0, 127.9, 126.8, 125.2, 123.1, 122.7, 110.1, 66.1, 51.3, 35.4, 24.4.

HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{19}\text{H}_{17}\text{ClN}_2\text{NaO}$ 347.0922; Found 347.0921.

(E)-9-Methyl-9-(2-methylstyryl)-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (3y)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (37.6 mg, 62%), mp 94.5-95.3 °C. ^1H NMR (CDCl_3 ,

400 MHz): δ 7.42-7.40 (m, 1H), 7.29-7.25 (m, 1H), 7.15-7.08 (m, 4H), 7.05 (td, J_1 = 7.2 Hz, J_2 = 0.8 Hz, 1H),

6.78 (d, $J = 7.6$ Hz, 1H), 6.74 (d, $J = 16.0$ Hz, 1H), 6.31 (d, $J = 15.6$ Hz, 1H), 3.85 (td, J_1 = 8.4 Hz, J_2 = 4.8 Hz,

1H), 3.53-3.47 (m, 1H), 3.02-2.94 (m, 1H), 2.85-2.77 (m, 1H), 2.28 (s, 3H), 2.05 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl₃, 100 MHz): δ 164.6, 147.2, 135.8, 135.5, 135.1, 131.7, 130.3, 128.9, 127.8, 127.4, 126.13, 126.11, 122.9, 122.7, 110.0, 66.4, 51.2, 35.4, 24.6, 19.8. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₂₀N₂NaO 327.1468; Found 327.1471.

(E)-9-(2-Chlorostyryl)-9-methyl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3z)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow oil (50.8 mg, 78%). ^1H NMR (CDCl₃, 400 MHz): 7.52 (dd, J_1 = 7.6 Hz, J_2 = 2.4 Hz, 1H), 7.32-7.26 (m, 2H), 7.20-7.12 (m, 3H), 7.06 (td, J_1 = 7.6 Hz, J_2 = 0.8 Hz, 1H), 6.93 (d, J = 16.0 Hz, 1H), 6.79 (d, J = 8.0 Hz, 1H), 6.46 (d, J = 16.0 Hz, 1H), 3.82 (td, J_1 = 8.8 Hz, J_2 = 5.6 Hz, 1H), 3.58-3.51 (m, 1H), 3.01-2.93 (m, 1H), 2.87-2.79 (m, 1H), 2.04 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl₃, 100 MHz): δ 164.6, 147.2, 134.5, 133.4, 133.0, 129.6, 129.0, 128.9, 127.3, 126.8, 125.8, 122.9, 122.8, 110.0, 66.2, 51.2, 35.3, 24.4. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₇ClN₂NaO 347.0922; Found 347.0918.

(E)-9-Methyl-9-(2-(naphthalen-1-yl)vinyl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3aa)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (46.7 mg, 69%), mp 46.3-47.2 °C. ^1H NMR (CDCl₃, 600 MHz): δ 8.01 (d, J = 8.4 Hz, 1H), 7.83-7.82 (m, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.58 (d, J = 7.2 Hz, 1H), 7.51-7.46 (m, 2H), 7.42-7.39 (m, 1H), 7.31-7.29 (m, 2H), 7.22 (d, J = 7.2 Hz, 1H), 7.09 (t, J = 7.8 Hz, 1H), 6.82 (d, J = 7.8 Hz, 1H), 6.48 (d, J = 15.6 Hz, 1H), 3.89 (td, J_1 = 8.4 Hz, J_2 = 4.8 Hz, 1H), 3.56-3.51 (m, 1H), 3.06-3.00 (m, 1H), 2.88-2.83 (m, 1H), 2.13 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl₃, 150 MHz): δ 164.8, 147.3, 135.0, 134.2, 133.7, 133.6, 131.3, 129.0, 128.6, 128.3, 126.8, 126.2, 125.9, 125.7, 124.4, 123.9, 123.0, 122.7, 110.1, 66.5, 51.3, 35.5, 24.8. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₃H₂₀N₂NaO 363.1468; Found 363.1457.

(E)-9-Methyl-9-(prop-1-en-1-yl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3bb)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow oil (29.0 mg, 64%). ^1H NMR (CDCl₃, 400 MHz): δ 7.26-7.22 (m, 1H), 7.07-7.00 (m, 2H), 6.75 (d, J = 8.0 Hz, 1H), 5.73 (dd, J_1 = 15.6 Hz, J_2 = 1.6 Hz, 1H), 5.67-5.60 (m, 1H), 3.83 (td, J_1 = 8.8 Hz, J_2 = 4.8 Hz, 1H), 3.47-3.40 (m, 1H), 3.01-2.92 (m, 1H), 2.80-2.73 (m,

1H), 1.92 (s, 3H), 1.69 (dd, $J_1 = 6.4$ Hz, $J_2 = 1.2$ Hz, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.3, 146.9, 135.6, 132.1, 128.7, 125.5, 122.8, 122.6, 109.9, 66.1, 51.2, 35.5, 24.5, 17.6. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{NaO}$ 251.1155; Found 251.1147.

(E)-9-(Hept-1-en-1-yl)-9-methyl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3cc)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow oil (39.9 mg, 70%). ^1H NMR (CDCl_3 , 400 MHz): δ 7.26-7.22 (m, 1H), 7.06-7.00 (m, 2H), 6.75 (d, $J = 8.0$ Hz, 1H), 5.71 (d, $J = 15.2$ Hz, 1H), 5.65-5.58 (m, 1H), 3.81 (td, $J_1 = 8.8$ Hz, $J_2 = 5.2$ Hz, 1H), 3.48-3.42 (m, 1H), 3.00-2.91 (m, 1H), 2.81-2.74 (m, 1H), 2.05-2.00 (m, 2H), 1.91 (s, 3H), 1.39-1.30 (m, 2H), 1.29-1.21 (m, 4H), 0.86 (t, $J = 6.8$ Hz, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.3, 147.0, 135.7, 130.9, 130.7, 128.6, 122.8, 122.6, 109.9, 66.1, 51.2, 35.5, 32.0, 31.5, 28.8, 24.6, 22.6, 14.1. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{NaO}$ 307.1781; Found 307.1788.

(E)-9-Methyl-9-(3-phenylprop-1-en-1-yl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3dd)

Eluent: petroleum ether/ethyl acetate (2:1). Yellow oil (36.4 mg, 60%). ^1H NMR (CDCl_3 , 600 MHz): δ 7.28 (t, $J = 7.8$ Hz, 2H), 7.24 (td, $J_1 = 7.8$ Hz, $J_2 = 1.2$ Hz, 1H), 7.19 (t, $J = 7.2$ Hz, 1H), 7.16 (d, $J = 6.6$ Hz, 2H), 7.06-7.04 (m, 1H), 7.01 (td, $J_1 = 7.2$ Hz, $J_2 = 0.6$ Hz, 1H), 6.76 (d, $J = 7.8$ Hz, 1H), 5.84-5.77 (m, 2H), 3.79 (td, $J_1 = 8.4$ Hz, $J_2 = 5.4$ Hz, 1H), 3.50-3.46 (m, 1H), 3.43-3.36 (m, 2H), 2.97-2.91 (m, 1H), 2.82-2.77 (m, 1H), 1.93 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.4, 147.1, 139.9, 135.4, 132.5, 129.2, 128.7, 128.5, 126.2, 122.9, 122.6, 109.9, 66.0, 51.2, 38.4, 35.4, 24.6. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{NaO}$ 327.1468; Found 327.1473.

(E)-2,9-dimethyl-9-styryl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (3ee)

Product **3ee** was obtained as a mixture of two diastereoisomers. **3ee-1**: Eluent: petroleum ether/ethyl acetate (3:1). Yellow oil (13.6 mg, 22%), ^1H NMR (CDCl_3 , 600 MHz): δ 7.40-7.33 (m, 2H), 7.28-7.25 (m, 3H), 7.21-7.16 (m, 2H), 7.05 (td, $J_1 = 7.2$ Hz, $J_2 = 0.6$ Hz, 1H), 6.78 (d, $J = 7.8$ Hz, 1H), 6.46 (d, $J = 16.2$ Hz, 1H), 6.38 (d, $J = 15.6$ Hz, 1H), 4.15 (t, $J = 7.8$ Hz, 1H), 3.21-3.17 (m, 1H), 2.95 (dd, $J_1 = 12.6$ Hz, $J_2 = 8.4$ Hz, 1H),

2.11 (s, 3H), 1.30 (d, J = 7.2 Hz, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 167.2, 147.0, 136.2, 134.9, 130.2, 128.9, 128.8, 128.5, 127.8, 126.8, 122.8, 122.5, 110.1, 66.3, 58.7, 40.8, 24.6, 13.5. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{NaO}$ 327.1468; Found 327.1475.

3ee-2: Eluent: petroleum ether/ethyl acetate (3:1). Yellow oil (22.6 mg, 37%). ^1H NMR (CDCl_3 , 400 MHz): δ 7.38 (d, J = 7.2 Hz, 2H), 7.30-7.20 (m, 4H), 7.11 (d, J = 7.2 Hz, 1H), 7.02 (t, J = 7.6 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 6.56 (d, J = 16.0 Hz, 1H), 6.49 (d, J = 16.0 Hz, 1H), 3.83 (t, J = 8.0 Hz, 1H), 3.31 (t, J = 7.6 Hz, 1H), 3.08-2.98 (m, 1H), 1.96 (s, 3H), 1.37 (d, J = 7.2 Hz, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 167.7, 147.2, 136.3, 135.0, 130.5, 129.5, 128.8, 128.5, 127.8, 126.9, 122.8, 122.7, 109.9, 65.9, 58.1, 41.3, 24.4, 14.6. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{NaO}$ 327.1468; Found 327.1477.

2. Typical procedure for the synthesis of **4a** and spectroscopic data of **4a-4t**

To a reaction tube equipped with a stir bar were charged with 1-phenylpyrazolidin-3-one (**1a**, 32.4 mg, 0.2 mmol), DCE (2 mL), $[\text{RhCp}^*\text{Cl}_2]_2$ (3.1 mg, 0.005 mmol), NaOAc (8.2 mg, 0.1 mmol) and 1-phenylbuta-2,3-dien-1-yl acetate (**2a**, 112.8 mg, 0.6 mmol). The tube was then sealed, and the mixture was stirred at 50 °C under argon for 6 h. Upon completion, it was quenched with saturated brine and extracted with dichloromethane (10 mL × 3). The combined organic phases were dried over anhydrous Na_2SO_4 , filtered through a pad of celite, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using petroleum ether/ethyl acetate (3:1) as eluent to afford **4a**. **4b-4t** were obtained in a similar manner.

9-Methyl-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4a**)**

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (61.2 mg, 73%), mp 77.7-78.7 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.40-7.39 (m, 2H), 7.35 (d, J = 7.2 Hz, 2H), 7.32-7.28 (m, 4H), 7.25-7.22 (m, 2H), 7.15 (dd, J_1 = 7.2 Hz, J_2 = 1.8 Hz, 1H), 7.13 (dd, J_1 = 7.2 Hz, J_2 = 1.2 Hz, 1H), 7.09 (t, J = 7.8 Hz, 1H), 7.02 (d, J = 16.2 Hz,

1H), 6.56 (d, $J = 15.6$ Hz, 1H), 6.46 (d, $J = 16.2$ Hz, 1H), 6.29 (d, $J = 16.2$ Hz, 1H), 5.58 (s, 1H), 5.34 (d, $J = 1.8$ Hz, 1H), 3.78 (td, $J_1 = 9.0$ Hz, $J_2 = 4.8$ Hz, 1H), 3.38-3.34 (m, 1H), 2.90-2.84 (m, 1H), 2.69-2.64 (m, 1H), 2.11 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.6, 144.8, 144.3, 136.9, 136.4, 135.6, 132.9, 130.5, 130.4, 129.2, 128.8, 128.6, 128.1, 127.9, 127.0, 126.8, 123.6, 122.9, 121.9, 119.8, 65.6, 50.9, 35.4, 24.5. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{29}\text{H}_{26}\text{N}_2\text{NaO}$ 441.1937; Found 441.1919.

7,9-Dimethyl-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4b)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (47.4 mg, 55%), mp 131.7-132.5 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.41 (d, $J = 7.2$ Hz, 2H), 7.36 (d, $J = 7.2$ Hz, 2H), 7.33-7.27 (m, 4H), 7.25-7.21 (m, 2H), 7.00 (d, $J = 16.0$ Hz, 1H), 6.95 (s, 1H), 6.93 (s, 1H), 6.58 (d, $J = 16.0$ Hz, 1H), 6.44 (d, $J = 16.0$ Hz, 1H), 6.31 (d, $J = 16.0$ Hz, 1H), 5.56 (s, 1H), 5.32 (s, 1H), 3.77-3.71 (m, 1H), 3.35-3.28 (m, 1H), 2.90-2.81 (m, 1H), 2.68-2.61 (m, 1H), 2.36 (s, 3H), 2.09 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 164.7, 144.9, 142.2, 136.9, 136.5, 135.9, 132.9, 132.7, 130.8, 130.7, 129.05, 129.00, 128.8, 128.6, 128.0, 127.9, 127.0, 126.9, 123.5, 122.4, 119.7, 65.6, 51.3, 35.5, 24.5, 21.1. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{30}\text{H}_{28}\text{N}_2\text{NaO}$ 455.2094; Found 455.2097.

7-Ethyl-9-methyl-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4c)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (45.6 mg, 51%), mp 131.0-131.6 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.41 (d, $J = 7.2$ Hz, 2H), 7.36 (d, $J = 7.8$ Hz, 2H), 7.32-7.28 (m, 4H), 7.25-7.22 (m, 2H), 7.01 (d, $J = 16.2$ Hz, 1H), 6.97 (s, 1H), 6.96 (s, 1H), 6.58 (d, $J = 15.6$ Hz, 1H), 6.45 (d, $J = 16.2$ Hz, 1H), 6.32 (d, $J = 15.6$ Hz, 1H), 5.57 (s, 1H), 5.34 (d, $J = 1.2$ Hz, 1H), 3.75 (td, $J_1 = 9.0$ Hz, $J_2 = 4.8$ Hz, 1H), 3.35-3.30 (m, 1H), 2.89-2.83 (m, 1H), 2.69-2.63 (m, 3H), 2.11 (s, 3H), 1.27 (t, $J = 7.8$ Hz, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.6, 144.9, 142.3, 139.1, 136.9, 136.4, 135.7, 132.8, 130.6, 129.6, 129.0, 128.9, 128.7, 128.5,

127.9, 127.8, 126.9, 126.8, 123.4, 121.1, 119.6, 65.6, 51.2, 35.4, 28.4, 24.4, 15.8. HRMS (ESI) m/z : [M+Na]⁺

Calcd for C₃₁H₃₀N₂NaO 469.2250; Found 469.2247.

7-(*tert*-Butyl)-9-methyl-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,

2-*a*]indazol-1-one (4d)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (57.6 mg, 61%), mp 76.5-77.5 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.41-7.39 (m, 2H), 7.35 (d, J = 7.2 Hz, 2H), 7.32-7.26 (m, 4H), 7.24-7.20 (m, 2H), 7.13 (s, 2H), 7.00 (d, J = 16.0 Hz, 1H), 6.57 (d, J = 16.0 Hz, 1H), 6.44 (d, J = 15.6 Hz, 1H), 6.32 (d, J = 16.0 Hz, 1H), 5.56 (s, 1H), 5.34 (d, J = 1.6 Hz, 1H), 3.76 (td, J_1 = 8.8 Hz, J_2 = 4.0 Hz, 1H), 3.34-3.27 (m, 1H), 2.90-2.82 (m, 1H), 2.67-2.60 (m, 1H), 2.11 (s, 3H), 1.33 (s, 9H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 163.6, 145.2, 144.1, 140.9, 135.9, 135.4, 134.3, 131.7, 129.6, 128.0, 127.8, 127.6, 127.5, 126.9, 126.7, 126.2, 125.9, 125.7, 121.8, 118.6, 117.5, 64.7, 49.9, 34.3, 33.6, 30.6, 23.4. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₃₃H₃₄N₂NaO 497.2563; Found 497.2554.

7-Fluoro-9-methyl-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]i

ndazol-1-one (4e)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (55.7 mg, 64%), mp 118.7-119.6 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.41-7.38 (m, 2H), 7.37-7.34 (m, 2H), 7.33-7.28 (m, 4H), 7.26-7.22 (m, 2H), 6.98 (d, J = 16.0 Hz, 1H), 6.88-6.84 (m, 2H), 6.56 (d, J = 15.6 Hz, 1H), 6.42 (d, J = 16.0 Hz, 1H), 6.30 (d, J = 16.0 Hz, 1H), 5.58 (s, 1H), 5.34 (d, J = 0.8 Hz, 1H), 3.76-3.70 (m, 1H), 3.34-3.27 (m, 1H), 2.89-2.80 (m, 1H), 2.68-2.61 (m, 1H), 2.08 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 164.6, 159.0 (d, $^1J_{C-F}$ = 249.4 Hz), 143.7, 140.6, 137.1 (d, $^3J_{C-F}$ = 7.9 Hz), 136.6, 136.1, 133.0, 129.9, 129.5, 128.7, 128.6, 128.3, 128.2, 128.0, 126.9, 126.8, 124.7 (d, $^3J_{C-F}$ = 7.3 Hz), 120.1, 116.8 (d, $^2J_{C-F}$ = 24.2 Hz), 109.2 (d, $^2J_{C-F}$ = 24.5 Hz), 65.6 (d, $^4J_{C-F}$ = 2.2 Hz), 51.2, 35.2, 24.3. ¹⁹F NMR (376 MHz, CDCl₃): δ -120.50 (t, J = 9.4 Hz). HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₂₉H₂₅FN₂NaO 459.1843; Found 459.1841.

7-Chloro-9-methyl-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4f)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (40.7 mg, 45%), mp 155.9-156.4 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.41-7.39 (m, 2H), 7.36-7.34 (m, 2H), 7.33-7.25 (m, 5H), 7.24-7.22 (m, 1H), 7.10 (s, 2H), 6.97 (d, *J* = 16.4 Hz, 1H), 6.57 (d, *J* = 16.0 Hz, 1H), 6.40 (d, *J* = 16.0 Hz, 1H), 6.27 (d, *J* = 16.0 Hz, 1H), 5.58 (s, 1H), 5.33 (s, 1H), 3.73 (td, *J*₁ = 8.8 Hz, *J*₂ = 4.8 Hz, 1H), 3.37-3.30 (m, 1H), 2.89-2.80 (m, 1H), 2.69-2.62 (m, 1H), 2.08 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 164.4, 143.6, 143.0, 137.3, 136.5, 136.1, 133.1, 130.0, 129.8, 129.5, 128.7, 128.6, 128.2, 128.1, 127.8, 126.9, 126.8, 124.7, 122.0, 120.2, 65.5, 50.7, 35.2, 24.3. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₉H₂₅ClN₂NaO 475.1548; Found 475.1557.

7-Bromo-9-methyl-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4g)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (61.7 mg, 62%), mp 99.2-99.9 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.40 (d, *J* = 7.6 Hz, 2H), 7.35 (d, *J* = 7.2 Hz, 2H), 7.33-7.26 (m, 5H), 7.25-7.22 (m, 3H), 6.97 (d, *J* = 16.0 Hz, 1H), 6.57 (d, *J* = 16.0 Hz, 1H), 6.40 (d, *J* = 16.0 Hz, 1H), 6.27 (d, *J* = 16.0 Hz, 1H), 5.58 (s, 1H), 5.32 (s, 1H), 3.73 (td, *J*₁ = 8.8 Hz, *J*₂ = 4.4 Hz, 1H), 3.37-3.31 (m, 1H), 2.89-2.80 (m, 1H), 2.69-2.62 (m, 1H), 2.07 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 164.4, 143.6, 143.4, 137.6, 136.5, 136.1, 133.2, 132.7, 129.8, 129.5, 128.7, 128.6, 128.2, 128.1, 127.0, 126.8, 125.1, 124.8, 120.2, 114.9, 65.4, 50.6, 35.2, 24.3. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₉H₂₅BrN₂NaO 519.1042; Found 519.1050.

9-Methyl-1-oxo-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazole-7-carbonitrile (4h)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (46.7 mg, 53%), mp 138.1-139.0 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.41-7.38 (m, 4H), 7.35-7.32 (m, 4H), 7.30-7.23 (m, 4H), 6.99 (d, *J* = 16.0 Hz, 1H), 6.55 (d, *J* = 15.6 Hz, 1H), 6.40 (d, *J* = 16.0 Hz, 1H), 6.19 (d, *J* = 16.0 Hz, 1H), 5.63 (s, 1H), 5.34 (s, 1H), 3.82

(td, J_1 = 9.2 Hz, J_2 = 4.8 Hz, 1H), 3.53-3.46 (m, 1H), 2.94-2.85 (m, 1H), 2.76-2.68 (m, 1H), 2.10 (s, 3H).

$^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.0, 147.0, 142.9, 136.5, 136.2, 135.7, 134.8, 133.4, 130.0, 129.2, 128.8, 128.7, 128.4, 128.3, 127.0, 126.8, 125.4, 123.4, 120.8, 118.9, 105.4, 65.4, 49.1, 35.0, 24.4. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{30}\text{H}_{25}\text{N}_3\text{NaO}$ 466.1890; Found 466.1872.

9-Methyl-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-7-(trifluoromethyl)-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (4i)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (46.4 mg, 48%), mp 109.3-110.3 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.40-7.38 (m, 3H), 7.36-7.34 (m, 3H), 7.33-7.28 (m, 4H), 7.26-7.23 (m, 2H), 7.00 (d, J = 16.2 Hz, 1H), 6.57 (d, J = 16.2 Hz, 1H), 6.42 (d, J = 16.2 Hz, 1H), 6.23 (d, J = 15.6 Hz, 1H), 5.62 (s, 1H), 5.36 (s, 1H), 3.81 (td, J_1 = 9.0 Hz, J_2 = 4.8 Hz, 1H), 3.46-3.41 (m, 1H), 2.91-2.86 (m, 1H), 2.72-2.67 (m, 1H), 2.12 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.3, 146.6, 143.7, 136.4, 136.2, 136.0, 133.2, 129.7, 129.5, 128.8, 128.6, 128.3, 128.1, 127.8 (q, $^3J_{\text{C}-\text{F}} = 3.3$ Hz), 127.0, 126.8, 125.0 (q, $^2J_{\text{C}-\text{F}} = 32.6$ Hz), 124.2 (q, $^1J_{\text{C}-\text{F}} = 270.3$ Hz), 123.2, 120.5, 118.9 (q, $^3J_{\text{C}-\text{F}} = 4.4$ Hz), 65.5, 49.8, 35.1, 24.3. ^{19}F NMR (565 MHz, CDCl_3): δ -61.20 (s). HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{30}\text{H}_{25}\text{F}_3\text{N}_2\text{NaO}$ 509.1811; Found 509.1803.

6-Fluoro-9-methyl-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H,9H*-pyrazolo[1,2-*a*]indazol-1-one (4j)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (35.7 mg, 41%), mp 91.5-92.4 °C. ^1H NMR (CDCl_3 , 600 MHz, 55 °C): δ 7.39-7.35 (m, 4H), 7.31-7.22 (m, 6H), 7.07 (dd, J_1 = 8.4 Hz, J_2 = 4.8 Hz, 1H), 7.03 (d, J = 16.2 Hz, 1H), 6.81 (t, J = 9.0 Hz, 1H), 6.54 (d, J = 15.6 Hz, 1H), 6.46 (d, J = 16.2 Hz, 1H), 6.26 (d, J = 16.2 Hz, 1H), 5.73 (s, 1H), 5.39 (s, 1H), 3.76 (br s, 1H), 3.42-3.41 (m, 1H), 2.87-2.81 (m, 1H), 2.69-2.64 (m, 1H), 2.08 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 164.2, 160.3 (d, $^1J_{\text{C}-\text{F}} = 244.5$ Hz), 136.5, 136.2, 132.4, 130.8, 130.2, 129.3, 128.7, 128.6, 128.1, 128.0, 126.9, 126.8, 122.7 (d, $^3J_{\text{C}-\text{F}} = 10.2$ Hz), 121.7, 111.6 (d, $^2J_{\text{C}-\text{F}}$

= 23.1 Hz), 109.7 (d, $^2J_{C-F}$ = 24.6 Hz), 65.3, 50.7, 35.3, 24.6. ^{19}F NMR (565 MHz, CDCl₃): δ -116.10 (s).

HRMS (ESI) m/z : [M+H]⁺ Calcd for C₂₉H₂₅FN₂NaO 459.1843; Found 459.1823.

2,2,9-Trimethyl-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4k)

Eluent: petroleum ether/ethyl acetate (5:1). Yellow solid (40.1 mg, 45%), mp 114.0-114.9 °C. 1H NMR (CDCl₃, 400 MHz): δ 7.39-7.34 (m, 3H), 7.33-7.31 (m, 2H), 7.30-7.27 (m, 3H), 7.25-7.21 (m, 3H), 7.16-7.11 (m, 2H), 7.05 (t, J = 7.2 Hz, 1H), 6.97 (d, J = 16.0 Hz, 1H), 6.53 (d, J = 15.6 Hz, 1H), 6.41 (d, J = 15.6 Hz, 1H), 6.34 (d, J = 16.4 Hz, 1H), 5.56 (s, 1H), 5.34 (d, J = 1.6 Hz, 1H), 3.54 (d, J = 8.4 Hz, 1H), 3.07 (d, J = 8.8 Hz, 1H), 2.10 (s, 3H), 1.25 (s, 3H), 1.17 (s, 3H). $^{13}C\{^1H\}$ NMR (CDCl₃, 150 MHz): δ 169.8, 144.8, 143.9, 136.9, 136.4, 135.5, 132.9, 130.5, 130.2, 128.7, 128.6, 128.5, 128.4, 127.9, 127.8, 126.9, 126.7, 123.3, 122.5, 121.6, 119.7, 65.3, 63.3, 45.5, 24.4, 22.8, 22.3. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₃₁H₃₀N₂NaO 469.2250; Found 469.2236.

2,9-Dimethyl-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4l, dr = 1.1:1)

4l-1: Eluent: petroleum ether/ethyl acetate (5:1). Yellow solid (19.0 mg, 22%), mp 57.2-58.2 °C. 1H NMR (CDCl₃, 400 MHz): δ 7.37-6.98 (m, 14H), 6.50 (d, J = 16.0 Hz, 1H), 6.39 (d, J = 16.0 Hz, 1H), 6.29 (d, J = 16.0 Hz, 1H), 5.57 (s, 1H), 5.33 (s, 1H), 4.07 (t, J = 8.4 Hz, 1H), 3.06-3.03 (m, 1H), 2.78 (dd, J_1 = 12.0 Hz, J_2 = 8.8 Hz, 1H), 2.16 (s, 3H), 1.19 (d, J = 7.2 Hz, 3H). $^{13}C\{^1H\}$ NMR (CDCl₃, 100 MHz): δ 167.2, 144.7, 144.1, 136.8, 136.3, 135.5, 132.8, 130.4, 130.2, 128.7, 128.5, 127.9, 127.8, 126.84, 126.76, 123.6, 122.7, 121.6, 119.7, 65.6, 58.2, 40.6, 24.6, 13.4. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₃₀H₂₈N₂NaO 455.2094; Found 455.2100.

4l-2: Eluent: petroleum ether/ethyl acetate (5:1). Yellow solid (17.4 mg, 20%), mp 57.7-58.7 °C. 1H NMR (CDCl₃, 400 MHz): δ 7.42-7.21 (m, 10H), 7.12-6.68 (m, 4H), 6.62 (d, J = 16.0 Hz, 1H), 6.53 (dd, J_1 = 16.0 Hz,

$J_2 = 2.0$ Hz, 1H), 6.32 (d, $J = 16.0$ Hz, 1H), 5.58 (s, 1H), 5.34 (s, 1H), 3.75 (t, $J = 8.0$ Hz, 1H), 3.14 (t, $J = 7.6$ Hz, 1H), 2.92-2.86 (m, 1H), 1.99 (s, 3H), 1.24-1.23 (m, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 167.3, 144.8, 144.2, 136.9, 136.4, 135.6, 132.8, 130.7, 130.2, 129.4, 128.9, 128.7, 128.5, 127.9, 127.8, 126.9, 126.7, 123.4, 122.6, 122.0, 119.8, 65.1, 57.7, 41.1, 24.4, 14.3. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{30}\text{H}_{28}\text{N}_2\text{NaO}$ 455.2094; Found 455.2090.

9-Methyl-9-((E)-4-methylstyryl)-5-((E)-4-(*p*-tolyl)buta-1,3-dien-2-yl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4m)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (63.9 mg, 72%), mp 48.4-49.4 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.28 (d, $J = 8.4$ Hz, 2H), 7.25-7.24 (m, 2H), 7.13-7.05 (m, 7H), 6.96 (d, $J = 15.6$ Hz, 1H), 6.51 (d, $J = 16.2$ Hz, 1H), 6.39 (d, $J = 16.2$ Hz, 1H), 6.26 (d, $J = 16.2$ Hz, 1H), 5.53 (s, 1H), 5.29 (d, $J = 1.8$ Hz, 1H), 3.76 (td, $J_1 = 9.0$ Hz, $J_2 = 4.2$ Hz, 1H), 3.36-3.31 (m, 1H), 2.88-2.82 (m, 1H), 2.66-2.62 (m, 1H), 2.32 (s, 6H), 2.08 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.4, 144.8, 144.2, 138.0, 137.7, 135.6, 134.0, 133.6, 132.7, 130.2, 129.5, 129.4, 129.2, 129.0, 128.1, 126.8, 126.7, 123.6, 122.7, 121.8, 119.2, 65.5, 50.8, 35.3, 24.5, 21.3, 21.2. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{31}\text{H}_{30}\text{N}_2\text{NaO}$ 469.2250; Found 469.2243.

5-((E)-4-(4-Fluorophenyl)buta-1,3-dien-2-yl)-9-((E)-4-fluorostyryl)-9-methyl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4n)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (54.1 mg, 60%), mp 140.2-150.2 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.36-7.33 (m, 2H), 7.30 (dd, $J_1 = 9.0$ Hz, $J_2 = 5.4$ Hz, 2H), 7.14 (dd, $J_1 = 7.2$ Hz, $J_2 = 1.8$ Hz, 1H), 7.11 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.8$ Hz, 1H), 7.08 (t, $J = 7.2$ Hz, 1H), 7.00-6.95 (m, 4H), 6.92 (d, $J = 16.2$ Hz, 1H), 6.51 (d, $J = 16.2$ Hz, 1H), 6.37 (d, $J = 15.6$ Hz, 1H), 6.23 (d, $J = 15.6$ Hz, 1H), 5.56 (s, 1H), 5.33 (d, $J = 1.2$ Hz, 1H), 3.76 (td, $J_1 = 8.4$ Hz, $J_2 = 4.2$ Hz, 1H), 3.38-3.33 (m, 1H), 2.89-2.83 (m, 1H), 2.69-2.64 (m, 1H), 2.09 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.5, 162.52 (d, ${}^1J_{\text{C-F}} = 245.3$ Hz), 162.49 (d, ${}^1J_{\text{C-F}} = 245.6$ Hz), 144.5, 144.2, 135.4, 133.0 (d, ${}^4J_{\text{C-F}} = 3.2$ Hz), 132.5 (d, ${}^4J_{\text{C-F}} = 3.5$ Hz), 131.5,

130.3, 130.2, 128.8, 128.4 (d, ${}^3J_{C-F} = 8.1$ Hz), 128.3 (d, ${}^3J_{C-F} = 7.2$ Hz), 127.9, 123.4, 122.9, 121.8, 119.8, 115.6 (d, ${}^2J_{C-F} = 21.5$ Hz), 115.5 (d, ${}^2J_{C-F} = 21.2$ Hz), 65.4, 50.8, 35.3, 24.4. ${}^{19}F$ NMR (565 MHz, $CDCl_3$): δ : -113.48 – -113.53 (m), -114.00 – -114.05 (m). HRMS (ESI) m/z : [M+Na]⁺ Calcd for $C_{29}H_{24}F_2N_2NaO$ 477.1749; Found 477.1740.

5-((E)-4-(4-Bromophenyl)buta-1,3-dien-2-yl)-9-((E)-4-bromostyryl)-9-methyl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4o)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (66.3 mg, 58%), mp 114.6-115.6 °C. 1H NMR ($CDCl_3$, 400 MHz): δ 7.43-7.39 (m, 4H), 7.26-7.23 (m, 2H), 7.19 (d, $J = 8.4$ Hz, 2H), 7.15-7.13 (m, 1H), 7.11-7.06 (m, 2H), 6.98 (d, $J = 16.0$ Hz, 1H), 6.49 (d, $J = 15.6$ Hz, 1H), 6.42 (d, $J = 16.0$ Hz, 1H), 6.20 (d, $J = 16.0$ Hz, 1H), 5.59 (s, 1H), 5.36 (d, $J = 0.8$ Hz, 1H), 3.76 (td, $J_1 = 8.8$ Hz, $J_2 = 4.4$ Hz, 1H), 3.37-3.30 (m, 1H), 2.91-2.82 (m, 1H), 2.70-2.62 (m, 1H), 2.08 (s, 3H). ${}^{13}C\{{}^1H\}$ NMR ($CDCl_3$, 150 MHz): δ 164.5, 144.4, 144.2, 135.7, 135.30, 135.27, 131.8, 131.7, 131.5, 131.2, 130.3, 129.6, 128.4, 128.2, 127.9, 123.3, 122.9, 121.9, 121.8, 121.7, 120.5, 65.4, 50.8, 35.3, 24.4. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $C_{29}H_{24}Br_2N_2NaO$ 597.0148; Found 597.0164.

4-((E)-2-(5-((E)-4-(4-Cyanophenyl)buta-1,3-dien-2-yl)-9-methyl-1-oxo-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-9-yl)vinyl)benzonitrile (4p)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (40.8 mg, 43%), mp 170.5-171.5 °C. 1H NMR ($CDCl_3$, 600 MHz): δ 7.59-7.55 (m, 4H), 7.46 (d, $J = 8.4$ Hz, 2H), 7.41 (d, $J = 8.4$ Hz, 2H), 7.16-7.14 (m, 1H), 7.12-7.09 (m, 3H), 6.60-6.54 (m, 2H), 6.26 (d, $J = 16.2$ Hz, 1H), 5.68 (s, 1H), 5.45 (s, 1H), 3.75 (td, $J_1 = 8.4$ Hz, $J_2 = 4.2$ Hz, 1H), 3.37-3.33 (m, 1H), 2.89-2.83 (m, 1H), 2.70-2.66 (m, 1H), 2.08 (s, 3H). ${}^{13}C\{{}^1H\}$ NMR ($CDCl_3$, 150 MHz): δ 164.7, 144.2, 144.0, 141.2, 140.8, 135.0, 134.3, 132.54, 132.45, 132.4, 130.8, 130.5, 127.5, 127.4, 127.1, 123.2, 122.9, 122.4, 122.0, 118.8, 111.2, 111.1, 65.4, 51.0, 35.2, 24.4. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $C_{31}H_{24}N_4NaO$ 491.1842; Found 491.1839.

9-Methyl-9-((E)-3-methylstyryl)-5-((E)-4-(*m*-tolyl)buta-1,3-dien-2-yl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4q)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (57.7 mg, 65%), mp 93.9-94.9 °C. ¹H NMR (CDCl₃, 600 MHz): δ 7.25 (s, 1H), 7.21-7.19 (m, 4H), 7.16-7.15 (m, 2H), 7.13 (dd, J₁ = 7.8 Hz, J₂ = 1.8 Hz, 1H), 7.09 (t, J = 7.2 Hz, 1H), 7.07-7.06 (m, 2H), 7.02 (d, J = 16.2 Hz, 1H), 6.53 (d, J = 16.2 Hz, 1H), 6.47 (d, J = 15.6 Hz, 1H), 6.28 (d, J = 16.2 Hz, 1H), 5.58 (s, 1H), 5.34 (d, J = 1.2 Hz, 1H), 3.79 (td, J₁ = 9.0 Hz, J₂ = 4.8 Hz, 1H), 3.38-3.34 (m, 1H), 2.91-2.85 (m, 1H), 2.69-2.64 (m, 1H), 2.34 (s, 3H), 2.30 (s, 3H), 2.12 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 164.4, 144.8, 144.3, 138.3, 138.1, 136.7, 136.3, 135.5, 133.0, 130.27, 130.26, 129.2, 128.8, 128.73, 128.65, 128.6, 128.4, 127.7, 127.5, 124.1, 123.8, 123.5, 122.8, 121.8, 119.6, 65.5, 50.8, 35.3, 24.4, 21.4, 21.3. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₃₁H₃₀N₂NaO 469.2250; Found 469.2251.

5-((E)-4-(3-Chlorophenyl)buta-1,3-dien-2-yl)-9-((E)-3-chlorostyryl)-9-methyl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4r)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (49.5 mg, 51%), mp 138.9-139.9 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.38 (s, 1H), 7.35 (s, 1H), 7.25-7.18 (m, 6H), 7.15-7.06 (m, 3H), 7.00 (d, J = 16.0 Hz, 1H), 6.51 (d, J = 16.0 Hz, 1H), 6.44 (d, J = 15.6 Hz, 1H), 6.20 (d, J = 16.0 Hz, 1H), 5.61 (s, 1H), 5.37 (d, J = 1.2 Hz, 1H), 3.76 (td, J₁ = 8.4 Hz, J₂ = 4.4 Hz, 1H), 3.37-3.31 (m, 1H), 2.92-2.83 (m, 1H), 2.70-2.63 (m, 1H), 2.09 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 164.6, 144.4, 144.2, 138.7, 138.2, 135.3, 134.7, 134.5, 131.9, 131.4, 130.3, 130.2, 129.9, 129.8, 127.9, 127.81, 127.75, 126.7, 126.5, 125.1, 125.0, 123.2, 123.0, 121.9, 120.8, 65.4, 50.8, 35.2, 24.3. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₂₉H₂₄Cl₂N₂NaO 509.1158; Found 509.1164.

9-Methyl-9-((E)-2-methylstyryl)-5-((E)-4-(*o*-tolyl)buta-1,3-dien-2-yl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4s)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (53.8 mg, 60%), mp 131.7-132.7 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.53 (d, $J = 7.2$ Hz, 1H), 7.43-7.41 (m, 1H), 7.20-7.06 (m, 9H), 6.86 (d, $J = 16.0$ Hz, 1H), 6.76 (d, $J = 15.6$ Hz, 1H), 6.56 (d, $J = 16.0$ Hz, 1H), 6.35 (dd, $J_1 = 16.0$ Hz, $J_2 = 1.2$ Hz, 1H), 5.56 (s, 1H), 5.34 (s, 1H), 3.75 (td, $J_1 = 8.4$ Hz, $J_2 = 4.4$ Hz, 1H), 3.43-3.36 (m, 1H), 2.88-2.80 (m, 1H), 2.71-2.64 (m, 1H), 2.29 (s, 3H), 2.11-2.10 (m, 6H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 164.4, 145.3, 143.9, 136.2, 135.9, 135.7, 135.4, 135.3, 131.8, 130.8, 130.4, 130.3, 130.2, 129.2, 127.8, 127.7, 127.2, 126.12, 126.07, 126.0, 125.2, 123.6, 122.9, 121.9, 119.6, 65.6, 50.7, 35.4, 24.6, 19.7, 19.6. HRMS (ESI) m/z : [M+Na] $^+$ Calcd for $\text{C}_{31}\text{H}_{30}\text{N}_2\text{NaO}$ 469.2250; Found 469.2253.

5-((E)-4-(2-Fluorophenyl)buta-1,3-dien-2-yl)-9-((E)-2-fluorostyryl)-9-methyl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (4t)

Eluent: petroleum ether/ethyl acetate (3:1). Yellow solid (38.1 mg, 42%), mp 84.6-85.6 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.47 (td, $J_1 = 7.8$ Hz, $J_2 = 1.8$ Hz, 1H), 7.43 (td, $J_1 = 7.8$ Hz, $J_2 = 1.2$ Hz 1H), 7.22-7.18 (m, 2H), 7.14 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.8$ Hz, 1H), 7.12 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.8$ Hz, 1H), 7.09-7.06 (m, 4H), 7.03-6.99 (m, 2H), 6.73 (d, $J = 16.2$ Hz, 1H), 6.57 (d, $J = 16.2$ Hz, 1H), 6.43 (d, $J = 16.2$ Hz, 1H), 5.61 (s, 1H), 5.38 (d, $J = 1.2$ Hz, 1H), 3.74 (td, $J_1 = 9.0$ Hz, $J_2 = 4.8$ Hz, 1H), 3.42-3.37 (m, 1H), 2.88-2.83 (m, 1H), 2.71-2.66 (m, 1H), 2.09 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.5, 160.5 (d, $^1J_{\text{C-F}} = 248.6$ Hz), 160.4 (d, $^1J_{\text{C-F}} = 248.1$ Hz), 144.8, 144.3, 135.3, 132.8 (d, $^4J_{\text{C-F}} = 3.9$ Hz), 131.5, 130.3, 129.1 (d, $^3J_{\text{C-F}} = 9.5$ Hz), 127.9 (d, $^3J_{\text{C-F}} = 8.1$ Hz), 127.8 (d, $^3J_{\text{C-F}} = 8.7$ Hz), 125.5, 124.8 (d, $^2J_{\text{C-F}} = 11.6$ Hz), 124.23, 124.16 (d, $^4J_{\text{C-F}} = 3.6$ Hz), 124.0 (d, $^4J_{\text{C-F}} = 3.2$ Hz), 123.2, 122.9, 122.0, 121.7 (d, $^4J_{\text{C-F}} = 3.3$ Hz), 120.6, 115.9 (d, $^2J_{\text{C-F}} = 21.9$ Hz), 115.7 (d, $^2J_{\text{C-F}} = 22.8$ Hz), 65.6, 50.9, 35.3, 24.3. ^{19}F NMR (565 MHz, CDCl_3): δ : -116.73 (s), -117.45 – -117.49 (m). HRMS (ESI) m/z : [M+Na] $^+$ Calcd for $\text{C}_{29}\text{H}_{24}\text{F}_2\text{N}_2\text{NaO}$ 477.1749; Found 477.1736.

3. Typical procedure for the synthesis of 5a and spectroscopic data of 5a-5d

To a reaction tube equipped with a stir bar were charged with 1-phenylpyrazolidin-3-one (**1a**, 64.8 mg, 0.4 mmol), DCE (2 mL), [RhCp^{*}Cl₂]₂ (3.1 mg, 0.005 mmol), NaOAc (8.2 mg, 0.1 mmol) and 1-phenylbuta-2,3-dien-1-yl acetate (**2a**, 37.6 mg, 0.2 mmol). The tube was then sealed, and the mixture was stirred at room temperature under argon for 2 h. Upon completion, it was quenched with water and extracted with dichloromethane (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. To the residue were added manganese dioxide (34.8 mg, 0.4 mmol) and acetic acid (2 mL). The resulting mixture was stirred at 100 °C for 12 h. Upon completion, it was cooled to room temperature, diluted with water, and extracted with dichloromethane (10 mL × 3). The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using petroleum ethyl acetate/methanol (20:1) as eluent to afford **5a**. **5b-5d** were obtained in a similar manner.

(E)-9-Methyl-9-styryl-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (5a)

Eluent: ethyl acetate/methanol (20:1). Yellow solid (23.1 mg, 40%), mp 50.7-51.7 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.60 (d, *J* = 3.2 Hz, 1H), 7.37-7.34 (m, 3H), 7.31-7.19 (m, 4H), 7.16 (t, *J* = 7.6 Hz, 1H), 7.11 (d, *J* = 8.0 Hz, 1H), 6.66-6.58 (m, 2H), 5.61 (d, *J* = 3.6 Hz, 1H), 2.12 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 161.8, 137.0, 135.9, 133.6, 130.5, 129.2, 128.5, 128.4, 128.1, 126.94, 126.92, 124.4, 123.9, 108.1, 100.5, 67.8, 24.2. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₆N₂NaO 311.1155; Found 311.1147.

(E)-7,9-Dimethyl-9-styryl-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (5b)

Eluent: ethyl acetate/methanol (20:1). Yellow solid (25.8 mg, 43%), mp 70.8-71.8 °C. ¹H NMR (CDCl₃, 600 MHz): δ 7.55 (d, *J* = 3.6 Hz, 1H), 7.37 (d, *J* = 7.2 Hz, 2H), 7.28-7.26 (m, 2H), 7.21 (t, *J* = 7.2 Hz, 1H), 7.15 (d, *J* = 8.4 Hz, 1H), 7.09 (s, 1H), 6.99 (d, *J* = 7.8 Hz, 1H), 6.63 (d, *J* = 16.2 Hz, 1H), 6.59 (d, *J* = 15.6 Hz, 1H), 5.57 (d, *J* = 3.6 Hz, 1H), 2.38 (s, 3H), 2.10 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 161.9, 137.3, 136.0,

134.5, 131.4, 130.4, 129.7, 128.6, 128.5, 128.1, 127.0, 126.7, 124.3, 107.8, 99.8, 67.7, 24.1, 21.2. HRMS (ESI)

m/z: [M+Na]⁺ Calcd for C₂₀H₁₈N₂NaO 325.1311; Found 325.1301.

(E)-7-Bromo-9-methyl-9-styryl-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (5c)

Eluent: ethyl acetate/methanol (20:1). Yellow solid (23.3 mg, 32%), mp 60.9-61.9 °C. ¹H NMR (CDCl₃, 600 MHz): δ 7.56 (d, *J* = 3.6 Hz, 1H), 7.48 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.8 Hz, 1H), 7.40 (d, *J* = 1.8 Hz, 1H), 7.38-7.37 (m, 2H), 7.30-7.28 (m, 2H), 7.25-7.24 (m, 1H), 6.98 (d, *J* = 8.4 Hz, 1H), 6.63 (d, *J* = 16.2 Hz, 1H), 6.55 (d, *J* = 16.2 Hz, 1H), 5.63 (d, *J* = 3.6 Hz, 1H), 2.11 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 161.7, 139.1, 135.6, 132.6, 132.2, 131.0, 128.6, 128.3, 127.8, 127.3, 127.1, 127.0, 116.8, 109.4, 101.3, 67.7, 24.1. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₅BrN₂NaO 389.0260; Found 389.0255.

(E)-9-(4-Bromostyryl)-9-methyl-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (5d)

Eluent: ethyl acetate/methanol (20:1). Yellow solid (35.1 mg, 48%), mp 74.7-75.7 °C. ¹H NMR (CDCl₃, 600 MHz): δ 7.59 (d, *J* = 3.6 Hz, 1H), 7.38-7.33 (m, 3H), 7.28 (d, *J* = 7.2 Hz, 1H), 7.21 (d, *J* = 8.4 Hz, 2H), 7.15 (t, *J* = 7.2 Hz, 1H), 7.10 (d, *J* = 7.8 Hz, 1H), 6.60 (d, *J* = 16.2 Hz, 1H), 6.54 (d, *J* = 16.2 Hz, 1H), 5.59 (d, *J* = 3.6 Hz, 1H), 2.09 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 161.8, 136.8, 134.9, 133.5, 131.6, 129.4, 129.3, 129.2, 128.5, 127.1, 124.5, 123.8, 121.9, 108.2, 100.5, 67.7, 24.1. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₅BrN₂NaO 389.0260; Found 389.0265.

4. Typical procedure for the synthesis of 6a and spectroscopic data of 6a-6e

To a reaction tube equipped with a stir bar were charged with **4a** (83.6 mg, 0.2 mmol), toluene (2 mL), sulfur (32.0 mg, 0.125 mmol) and 4Å molecular sieve (33.4 mg). The tube was then sealed, and the mixture was stirred at 180 °C for 18 h. Upon completion, it was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silical gel column chromatography with petroleum ether/ethyl acetate (2:1) as the eluent to give **6a**. **6b-6e** were obtained in a similar manner.

(E)-9-Methyl-5-(5-phenylthiophen-3-yl)-9-styryl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (6a)

Eluent: petroleum ether/ethyl acetate (3:1). White solid (62.0 mg, 69%), mp 173.6-174.6 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.65 (d, $J = 7.2$ Hz, 2H), 7.55 (s, 1H), 7.42-7.39 (m, 4H), 7.36 (s, 1H), 7.33-7.28 (m, 4H), 7.22 (t, $J = 7.2$ Hz, 1H), 7.13-7.11 (m, 2H), 6.57 (d, $J = 16.2$ Hz, 1H), 6.47 (d, $J = 16.2$ Hz, 1H), 3.63-3.60 (m, 1H), 3.19-3.15 (m, 1H), 2.89-2.83 (m, 1H), 2.65-2.61 (m, 1H), 2.10 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 165.2, 144.9, 144.5, 139.2, 136.3, 135.7, 134.0, 130.6, 129.5, 129.3, 129.1, 128.5, 127.94, 127.89, 126.9, 125.9, 123.9, 123.5, 122.6, 121.8, 121.2, 65.8, 51.9, 35.1, 24.9. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{29}\text{H}_{24}\text{N}_2\text{NaOS}$ 471.1502; Found 471.1508.

(E)-7,9-Dimethyl-5-(5-phenylthiophen-3-yl)-9-styryl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one

(6b)

Eluent: petroleum ether/ethyl acetate (3:1). White solid (32.4 mg, 35%), mp 92.0-93.0 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.65 (d, $J = 7.2$ Hz, 2H), 7.54 (d, $J = 0.8$ Hz, 1H), 7.42-7.38 (m, 4H), 7.35-7.28 (m, 4H), 7.22 (t, $J = 7.2$ Hz, 1H), 7.13 (s, 1H), 6.93 (s, 1H), 6.58 (d, $J = 16.0$ Hz, 1H), 6.46 (d, $J = 16.0$ Hz, 1H), 3.59 (td, $J_1 = 8.8$ Hz, $J_2 = 4.4$ Hz, 1H), 3.17-3.11 (m, 1H), 2.89-2.81 (m, 1H), 2.65-2.58 (m, 1H), 2.38 (s, 3H), 2.08 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 165.3, 144.8, 142.4, 139.3, 136.3, 136.0, 134.0, 133.3, 130.7, 130.0, 129.2, 129.0, 128.5, 127.9, 127.8, 126.9, 125.9, 123.9, 122.5, 122.3, 121.0, 65.9, 52.3, 35.2, 24.8, 21.0. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{30}\text{H}_{26}\text{N}_2\text{NaOS}$ 485.1658; Found 485.1661.

(E)-7-Chloro-9-methyl-5-(5-phenylthiophen-3-yl)-9-styryl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (6c)

Eluent: petroleum ether/ethyl acetate (3:1). White solid (36.9 mg, 38%), mp 170.0-171.0 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.65-7.63 (m, 2H), 7.51 (d, $J = 1.6$ Hz, 1H), 7.42-7.39 (m, 4H), 7.37 (d, $J = 1.2$ Hz, 1H), 7.34-7.28 (m, 4H), 7.25-7.22 (m, 1H), 7.08 (d, $J = 2.0$ Hz, 1H), 6.58 (d, $J = 15.6$ Hz, 1H), 6.42 (d, $J = 16.0$ Hz, 1H), 3.59 (td, $J_1 = 8.8$ Hz, $J_2 = 4.4$ Hz, 1H), 3.19-3.12 (m, 1H), 2.90-2.81 (m, 1H), 2.67-2.59 (m, 1H), 2.08 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 165.2, 145.3, 143.2, 137.8, 137.5, 136.0, 133.8, 130.0, 129.8, 129.2,

129.1, 128.6, 128.5, 128.12, 128.08, 126.9, 125.9, 123.5, 123.1, 122.4, 121.8, 65.9, 51.9, 34.9, 24.8. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₂₉H₂₃ClN₂NaOS 505.1112; Found 505.1108.

(E)-9-Methyl-9-(4-methylstyryl)-5-(5-(*p*-tolyl)thiophen-3-yl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (6d)

Eluent: petroleum ether/ethyl acetate (3:1). White solid (47.8 mg, 50%), mp 149.3-150.3 °C. ¹H NMR (CDCl₃, 600 MHz): δ 7.54 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 1.2 Hz, 1H), 7.31-7.27 (m, 4H), 7.20 (d, J = 7.8 Hz, 2H), 7.12-7.09 (m, 4H), 6.52 (d, J = 16.2 Hz, 1H), 6.42 (d, J = 16.2 Hz, 1H), 3.61 (td, J_1 = 9.0 Hz, J_2 = 4.8 Hz, 1H), 3.18-3.14 (m, 1H), 2.88-2.82 (m, 1H), 2.64-2.59 (m, 1H), 2.37 (s, 3H), 2.31 (s, 3H), 2.08 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 165.2, 145.0, 144.5, 139.1, 137.9, 137.7, 135.8, 133.5, 131.2, 129.7, 129.6, 129.5, 129.2, 126.8, 125.8, 123.42, 123.41, 122.1, 121.8, 121.3, 65.9, 51.9, 35.1, 24.9, 21.2. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₃₁H₂₈N₂NaOS 499.1815; Found 499.1835.

(E)-5-(5-(4-Bromophenyl)thiophen-3-yl)-9-(4-bromostyryl)-9-methyl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (6e)

Eluent: petroleum ether/ethyl acetate (3:1). White solid (48.4 mg, 40%), mp 82.1-83.1 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.54-7.49 (m, 5H), 7.42-7.37 (m, 3H), 7.32-7.28 (m, 1H), 7.26-7.24 (m, 2H), 7.13-7.12 (m, 2H), 6.51 (d, J = 16.0 Hz, 1H), 6.45 (d, J = 15.6 Hz, 1H), 3.60 (td, J_1 = 8.8 Hz, J_2 = 4.4 Hz, 1H), 3.19-3.13 (m, 1H), 2.91-2.82 (m, 1H), 2.67-2.59 (m, 1H), 2.08 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 165.3, 144.5, 143.6, 139.3, 135.6, 135.2, 132.9, 132.2, 131.6, 131.4, 129.6, 128.4, 128.2, 127.3, 124.2, 123.6, 123.0, 121.9, 121.8, 121.7, 121.0, 65.8, 52.0, 35.0, 24.8. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₂₉H₂₂Br₂N₂NaOS 626.9712; Found 626.9704.

5. Typical procedure for the synthesis of 7a and spectroscopic data of 7a-7e

To a reaction tube equipped with a stir bar were charged with **4a** (83.6 mg, 0.2 mmol), toluene (2 mL) and dimethyl but-2-ynedioate (56.8 mg, 0.4 mmol). The tube was then sealed, and the mixture was stirred at

120 °C for 12 h. Upon completion, it was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with petroleum ether/ethyl acetate (1:1) as the eluent to give **7a** as a mixture of two diastereoisomers. **7b-7e** were obtained in a similar manner.

Dimethyl (E)-5-(9-methyl-1-oxo-9-styryl-2,3-dihydro-1H,9H-pyrazolo[1,2-a]indazol-5-yl)-1,4-dihydro-[1,1'-biphenyl]-2,3-dicarboxylate (7a)

Eluent: petroleum ether/ethyl acetate (1:1). Yellow solid (88.6 mg, 79% , dr = 1:2.3). ¹H NMR (CDCl₃, 600 MHz): δ 7.29-7.23 (m, 3H), 7.21-7.11 (m, 7H), 7.05-6.94 (m, 3H), 6.43-6.40 (m, 1H), 6.35-6.32 (m, 1H), 5.90-5.88 (m, 1H), 4.56-4.52 (m, 1H), 3.74-3.73 (m, 3H), 3.63-3.58 (m, 0.3H), 3.51-3.50 (m, 3H), 3.48-3.46 (m, 0.7H), 3.44-3.31 (m, 1.7H), 3.23-3.14 (m, 1.3H), 2.86-2.81 (m, 0.3H), 2.74-2.68 (m, 0.7H), 2.61-2.54 (m, 1H), 1.961-1.956 (m, 3H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 167.9, 167.84, 167.75, 167.69, 165.0, 164.9, 144.0, 143.9, 140.8, 140.7, 136.2, 135.9, 135.7, 135.5, 135.4, 132.4, 131.7, 130.52, 130.47, 129.8, 129.6, 129.3, 128.95, 128.87, 128.52, 128.49, 128.4, 128.2, 127.9, 127.8, 127.5, 126.8, 125.2, 125.0, 123.3, 122.0, 121.9, 65.7, 65.6, 52.54, 52.50, 52.20, 52.18, 52.0, 45.2, 45.1, 35.1, 30.3, 24.9, 24.8. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₃₅H₃₂N₂NaO₅ 583.2203; Found 583.2200.

Dimethyl (E)-5-(7,9-dimethyl-1-oxo-9-styryl-2,3-dihydro-1H,9H-pyrazolo[1,2-a]indazol-5-yl)-1,4-dihydro-[1,1'-biphenyl]-2,3-dicarboxylate (7b)

Eluent: petroleum ether/ethyl acetate (1:1). Yellow solid (92.9 mg, 81% , dr = 1:1). ¹H NMR (CDCl₃, 600 MHz): δ 7.37-7.31 (m, 3H), 7.30-7.19 (m, 7H), 6.93 (s, 0.5H), 6.89 (s, 0.5H), 6.86 (s, 1H), 6.51 (d, *J* = 16.2 Hz, 1H), 6.39 (d, *J* = 16.2 Hz, 1H), 5.97-5.95 (m, 1H), 4.61 (br s, 1H), 3.81 (s, 3H), 3.782-3.775 (m, 0.5H), 3.70-3.65 (m, 0.5H), 3.58-3.57 (m, 3H), 3.52-3.38 (m, 1.5H), 3.26-3.17 (m, 1.5H), 2.90-2.86 (m, 0.5H), 2.80-2.74 (m, 0.5H), 2.67-2.61 (m, 1H), 2.31-2.30 (m, 3H), 2.02 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 168.0, 167.83, 167.81, 167.7, 165.1, 165.0, 141.84, 141.81, 140.9, 140.8, 136.3, 136.0, 135.9, 135.8, 135.3, 133.2, 132.6, 131.8, 130.7, 130.6, 129.8, 129.6, 129.2, 128.95, 128.90, 128.87, 128.7, 128.51, 128.49, 128.27,

128.26, 127.9, 127.8, 127.7, 127.6, 127.4, 126.9, 125.1, 124.9, 122.5, 122.4, 65.7, 65.6, 52.5, 52.4, 52.3, 52.2, 52.1, 45.3, 45.1, 35.2, 30.4, 30.3, 24.8, 24.7, 20.95, 20.92. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₃₆H₃₄N₂NaO₅ 597.2360; Found 597.2375.

Dimethyl (E)-5-(7-chloro-9-methyl-1-oxo-9-styryl-2,3-dihydro-1H,9H-pyrazolo[1,2-a]indazol-5-yl)-1,4-dihydro-[1,1'-biphenyl]-2,3-dicarboxylate (7c)

Eluent: petroleum ether/ethyl acetate (1:1). Yellow solid (71.0 mg, 60%, dr = 1:1). ¹H NMR (CDCl₃, 400 MHz): δ 7.30-7.11 (m, 10H), 7.03-6.98 (m, 1H), 6.95-6.94 (m, 1H), 6.46-6.41 (m, 1H), 6.28 (d, J = 16.0 Hz, 1H), 5.91-5.90 (m, 1H), 4.55-4.52 (m, 1H), 3.742-3.738 (m, 3H), 3.71-3.67 (m, 0.5H), 3.60-3.52 (m, 0.5H), 3.50-3.49 (m, 3H), 3.47-3.41 (m, 0.5H), 3.36-3.33 (m, 1H), 3.20-3.10 (m, 1.5H), 2.86-2.78 (m, 0.5H), 2.74-2.65 (m, 0.5H), 2.61-2.52 (m, 1H), 1.94-1.93 (m, 3H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 166.7, 166.6, 166.5, 163.9, 163.8, 141.64, 141.61, 139.4, 139.3, 136.5, 136.3, 134.89, 134.86, 134.4, 131.0, 130.3, 128.82, 128.76, 128.70, 128.68, 128.0, 127.9, 127.7, 127.64, 127.56, 127.53, 127.50, 127.40, 127.36, 127.2, 127.02, 126.99, 126.98, 126.54, 126.53, 125.8, 125.3, 125.1, 121.02, 120.96, 64.7, 64.6, 51.5, 51.17, 51.15, 50.9, 50.7, 44.2, 44.0, 33.9, 29.1, 29.0, 23.7, 23.6. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₃₅H₃₁ClN₂NaO₅ 617.1814; Found 617.1807.

Dimethyl (E)-4'-methyl-5-(9-methyl-9-(4-methylstyryl)-1-oxo-2,3-dihydro-1H,9H-pyrazolo[1,2-a]indazol-5-yl)-1,4-dihydro-[1,1'-biphenyl]-2,3-dicarboxylate (7d)

Eluent: petroleum ether/ethyl acetate (1:1). Yellow solid (74.5 mg, 63%, dr = 1:1). ¹H NMR (CDCl₃, 400 MHz): δ 7.26-7.23 (m, 2H), 7.15-6.99 (m, 9H), 6.48-6.43 (m, 1H), 6.36 (d, J = 16.0 Hz, 1H), 5.95-5.93 (m, 1H), 4.61-4.54 (m, 1H), 3.81-3.80 (m, 3H), 3.73-3.62 (m, 0.5H), 3.59-3.58 (m, 3H), 3.56-3.52 (m, 1H), 3.46-3.41 (m, 1H), 3.37-3.18 (m, 1.5H), 2.95-2.86 (m, 0.5H), 2.83-2.74 (m, 0.5H), 2.69-2.60 (m, 1H), 2.32-2.30 (m, 6H), 2.03-2.02 (m, 3H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 167.9, 167.79, 167.76, 164.94, 164.86, 143.97, 143.95, 137.74, 137.70, 137.66, 137.11, 137.09, 136.2, 135.8, 135.6, 133.4, 132.1, 131.4,

129.62, 129.55, 129.53, 129.48, 129.4, 129.21, 129.18, 128.4, 128.2, 128.12, 128.09, 128.0, 127.9, 126.7, 125.3, 125.1, 123.30, 123.28, 122.0, 121.9, 65.72, 65.67, 52.5, 52.18, 52.16, 52.0, 51.9, 44.9, 44.7, 35.1, 30.3, 30.2, 24.90, 24.85, 21.2, 21.12, 21.11. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₃₇H₃₆N₂NaO₅ 611.2516; Found 611.2519.

Dimethyl (*E*)-4'-bromo-5-(9-(4-bromostyryl)-9-methyl-1-oxo-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-5-yl)-1,4-dihydro-[1,1'-biphenyl]-2,3-dicarboxylate (7e)

Eluent: petroleum ether/ethyl acetate (1:1). Yellow solid (105.9 mg, 74% , dr = 1:1). ¹H NMR (CDCl₃, 400 MHz): δ 7.47-7.37 (m, 4H), 7.23-7.20 (m, 2H), 7.13-7.01 (m, 5H), 6.44 (d, *J* = 16.0 Hz, 1H), 6.41-6.36 (m, 1H), 5.93-5.91 (m, 1H), 4.62-4.56 (m, 1H), 3.818-3.815 (m, 3H), 3.75-3.64 (m, 1H), 3.61-3.60 (m, 3H), 3.57-3.41 (m, 1.5H), 3.38-3.20 (m, 1.5H), 2.97-2.88 (m, 0.5H), 2.85-2.79 (m, 0.5H), 2.73-2.63 (m, 1H), 2.03 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 167.9, 167.7, 167.5, 167.3, 165.1, 165.0, 143.93, 143.86, 139.93, 139.87, 135.5, 135.3, 135.17, 135.15, 134.8, 134.3, 133.3, 132.6, 132.1, 132.0, 131.63, 131.61, 131.3, 131.2, 130.3, 130.0, 129.9, 128.5, 128.4, 128.23, 128.18, 127.3, 127.2, 125.0, 124.9, 123.5, 122.1, 122.0, 121.70, 121.69, 121.4, 65.7, 65.6, 52.6, 52.31, 52.29, 52.1, 51.9, 44.6, 44.4, 35.1, 35.0, 30.5, 30.3, 24.82, 24.75. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₃₅H₃₀Br₂N₂NaO₅ 739.0414; Found 739.0406.

6. Synthesis of 8 and its spectroscopic data

To a reaction tube equipped with a stir bar were charged with **4a** (41.8 mg, 0.1 mmol), toluene (2 mL) and *N*-methylmaleimide (22.2 mg, 0.2 mmol). The tube was then sealed, and the mixture was stirred at 120 °C for 12 h. Upon completion, it was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with petroleum ether/ethyl acetate (1:2) as the eluent to give product **8** as a mixture of two diastereoisomers.

(*E*)-2-Methyl-6-(9-methyl-1-oxo-9-styryl-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-5-yl)-4-phenyl-3a,4,7,7a-tetrahydro-1*H*-isoindole-1,3(2*H*)-dione (8)

8-1: Eluent: petroleum ether/ethyl acetate (1:2). White solid (18.7 mg, 35%), mp 106.3-107.0 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.40-7.37 (m, 4H), 7.33-7.26 (m, 5H), 7.22 (t, J = 7.8 Hz, 1H), 7.12-7.06 (m, 3H), 6.53 (d, J = 15.6 Hz, 1H), 6.50-6.49 (m, 1H), 6.45 (d, J = 16.2 Hz, 1H), 3.92 (t, J = 5.4 Hz, 1H), 3.65 (td, J_1 = 9.0 Hz, J_2 = 5.4 Hz, 1H), 3.46-3.43 (m, 1H), 3.40 (td, J_1 = 7.8 Hz, J_2 = 1.8 Hz, 1H), 3.34-3.30 (m, 1H), 3.24 (dd, J_1 = 16.8 Hz, J_2 = 2.4 Hz, 1H), 2.91-2.86 (m, 1H), 2.84-2.79 (m, 1H), 2.75 (s, 3H), 2.73-2.68 (m, 1H), 2.03 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 177.8, 175.6, 163.6, 142.7, 137.5, 135.6, 135.2, 134.8, 129.5, 128.51, 128.46, 127.7, 127.5, 127.44, 127.1, 126.8, 126.4, 125.8, 124.1, 122.5, 120.9, 64.4, 50.0, 44.4, 41.2, 38.8, 33.9, 26.6, 23.7, 23.6. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{34}\text{H}_{31}\text{N}_3\text{NaO}_3$ 552.2258; Found 552.2269.

8-2: Eluent: petroleum ether/ethyl acetate (1:2). White solid (18.6 mg, 35%), mp 117.1-118.1 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.30-7.27 (m, 4H), 7.24-7.17 (m, 5H), 7.13 (t, J = 7.2 Hz, 1H), 7.10 (dd, J_1 = 7.8 Hz, J_2 = 1.2 Hz, 1H), 7.04 (t, J = 7.8 Hz, 1H), 7.00 (dd, J_1 = 7.2 Hz, J_2 = 1.2 Hz, 1H), 6.43 (d, J = 16.2 Hz, 1H), 6.39-6.38 (m, 1H), 6.31 (d, J = 16.2 Hz, 1H), 3.84 (t, J = 5.4 Hz, 1H), 3.75 (td, J_1 = 8.4 Hz, J_2 = 3.6 Hz, 1H), 3.38-3.35 (m, 1H), 3.33-3.30 (m, 1H), 3.26 (dd, J_1 = 16.2 Hz, J_2 = 1.8 Hz, 1H), 3.13-3.08 (m, 1H), 2.86-2.80 (m, 1H), 2.70 (s, 3H), 2.62-2.57 (m, 2H), 1.99 (s, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 178.0, 175.4, 163.7, 143.2, 137.5, 135.3, 135.1, 134.9, 129.3, 128.7, 128.1, 127.8, 127.5, 127.4, 127.1, 126.8, 126.4, 125.8, 123.8, 122.6, 120.7, 64.5, 49.8, 44.9, 41.5, 39.2, 33.8, 27.5, 23.7, 23.6. HRMS (ESI) m/z : [M+Na]⁺ Calcd for $\text{C}_{34}\text{H}_{31}\text{N}_3\text{NaO}_3$ 552.2258; Found 552.2265.

7. Synthesis of 9 and its spectroscopic data

To a reaction tube equipped with a stir bar was charged with **4g** (99.2 mg, 0.2 mmol), dioxane (2 mL), $\text{Pd}_2(\text{dba})_3$ (18.3 mg, 0.02 mmol), DavePhos (11.8 mg, 0.03 mmol), $^7\text{BuONa}$ (38.4 mg, 0.4 mmol) and morpholine (52.3 mg, 0.6 mmol). The tube was then sealed, and the mixture was stirred at 100 °C under argon for 12 h. Upon completion, it was cooled to room temperature, diluted with dichloromethane (20 mL) and washed with water and brine. The organic layer was dried over anhydrous Na_2SO_4 , filtered, and concentrated

under reduced pressure. The residue was purified by silica gel column chromatography with petroleum ether/ethyl acetate (2:1) as eluent to afford **9**.

9-Methyl-7-morpholino-5-((E)-4-phenylbuta-1,3-dien-2-yl)-9-((E)-styryl)-2,3-dihydro-1*H*,9*H*-pyrazolo[1,2-*a*]indazol-1-one (9**)**

Eluent: petroleum ether/ethyl acetate (2:1). Yellow solid (46.4 mg, 46%), mp 112.2-113.2 °C. ¹H NMR (CDCl₃, 600 MHz): δ 7.39 (d, *J* = 7.2 Hz, 2H), 7.35 (d, *J* = 7.2 Hz, 2H), 7.33-7.28 (m, 4H), 7.23 (td, *J*₁ = 7.2 Hz, *J*₂ = 1.2 Hz, 2H), 6.99 (d, *J* = 16.2 Hz, 1H), 6.72 (s, 1H), 6.68 (s, 1H), 6.58 (d, *J* = 15.6 Hz, 1H), 6.43 (d, *J* = 15.6 Hz, 1H), 6.32 (d, *J* = 16.2 Hz, 1H), 5.56 (s, 1H), 5.33 (d, *J* = 1.2 Hz, 1H), 3.86 (t, *J* = 4.2 Hz, 4H), 3.69 (td, *J*₁ = 8.4 Hz, *J*₂ = 4.8 Hz, 1H), 3.31-3.26 (m, 1H), 3.13 (t, *J* = 4.2 Hz, 4H), 2.86-2.80 (m, 1H), 2.66-2.61 (m, 1H), 2.08 (s, 3H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 164.7, 145.0, 136.8, 136.3, 132.9, 130.4, 129.1, 128.8, 128.7, 128.5, 128.0, 127.9, 126.9, 126.8, 124.3, 119.6, 118.1, 110.2, 66.9, 65.7, 51.7, 50.5, 35.4, 24.3. HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₃₃H₃₄N₃O₂ 504.2646; Found 504.2637.

8. Gram-scale synthesis of **3a**

To a reaction tube equipped with a stir bar were charged with **1a** (1.6208 g, 10 mmol), DCE (20 mL), [RhCp^{*}Cl₂]₂ (77.3 mg, 0.125 mmol), NaOAc (205 mg, 2.5 mmol) and **2a** (940.4 mg, 5 mmol). The tube was then sealed, and the mixture was stirred at room temperature under argon for 12 h. Upon completion, it was quenched with saturated brine and extracted with dichloromethane (30 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered through a pad of celite, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with petroleum ether/ethyl acetate (2:1) as eluent to afford **3a** (1.059 g, 73%).

9. Gram-scale synthesis of **4a**


To a reaction tube equipped with a stir bar were charged with **1a** (648.3 mg, 4 mmol), DCE (20 mL), [RhCp^{*}Cl₂]₂ (61.8 mg, 0.1 mmol), NaOAc (164 mg, 2 mmol) and **2a** (2.2570 g, 12 mmol). The tube was then

sealed, and the mixture was stirred at 50 °C under argon for 24 h. Upon completion, it was quenched with saturated brine and extracted with dichloromethane (30 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered through a pad of celite, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with petroleum ether/ethyl acetate (3:1) as eluent to afford **4a** (932.2 mg, 55%).

III. Mechanistic studies



1. H/D exchange experiment (I)

To a reaction tube equipped with a stir bar were charged with **1a** (32.4 mg, 0.2 mmol), DCE (2 mL), CD₃OD (163 µL, 4 mmol), [RhCp*Cl₂]₂ (3.1 mg, 0.005 mmol) and NaOAc (8.2 mg, 0.1 mmol). The tube was then sealed, and the mixture was stirred at room temperature under argon for 0.5 h. Afterwards, it was quenched with saturated brine and extracted with dichloromethane (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using petroleum ether/ethyl acetate (2:1) as eluent to give a mixture of **1a** and **1a-d₂**. Upon analyzing the ¹H NMR spectrum of the mixture, the deuteration ratio was determined to be 15%.



2. H/D exchange experiment (II)


To a reaction tube equipped with a stir bar were charged with **1a** (64.8 mg, 0.4 mmol), **2a** (37.7 mg, 0.2 mmol), DCE (2 mL), CD₃OD (163 µL, 4 mmol), [RhCp*Cl₂]₂ (3.1 mg, 0.005 mmol) and NaOAc (8.2 mg, 0.1 mmol). The tube was then sealed, and the mixture was stirred at room temperature under argon for 0.5 h. Afterwards, it was quenched with saturated brine and extracted with dichloromethane (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using petroleum ether/ethyl acetate (2:1) as eluent to give a mixture of **3a** and **3a-d₁**. Upon analyzing the ¹H NMR spectrum of the mixture, the deuteration ratio was determined to be about 9%.



3. Kinetic isotope effect study

To a reaction tube equipped with a stir bar were charged with **1a** (16.7 mg, 0.1 mmol), **1a-d₅** (16.2 mg, 0.1 mmol), **2a** (18.8 mg, 0.1 mmol), DCE (1 mL), [RhCp*Cl₂]₂ (1.6 mg, 0.0025 mmol) and NaOAc (4.1 mg, 0.05 mmol). The tube was then sealed, and the mixture was stirred at room temperature under argon for 0.5 h.

Afterwards, it was quenched with saturated brine and extracted with dichloromethane (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using petroleum ether/ethyl acetate (2:1) as eluent to give a mixture of **3a** and **3a-d₄**. Upon analyzing the ¹H NMR spectrum of the mixture, the ratio of **3a** to **3a-d₄** was determined to be about 0.75:0.25. Accordingly, the intermolecular KIE (*k*_H/*k*_D) was calculated to be about 3.0.



4. Electronic competition experiment

To a reaction tube equipped with a stir bar were added **1b** (35.2 mg, 0.2 mmol), **1e** (46.0 mg, 0.2 mmol), **2a** (37.7 mg, 0.2 mmol), [RhCp^{*}Cl₂]₂ (3.1 mg, 0.005 mmol), NaOAc (8.2 mg, 0.1 mmol) and DCE (2 mL). The tube was then sealed, and the mixture was stirred at room temperature for 0.5 h. Afterwards, it was quenched with saturated brine and extracted with dichloromethane (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by

silica gel column chromatography using petroleum ether/ethyl acetate (2:1) as eluent to give **3e** (36.5 mg, 51%). Meanwhile, product **3b** was formed in trace amount.



5. Controle experiment

To a reaction tube equipped with a stir bar were added **3a** (29.0 mg, 0.1 mmol), **2a** (41.8 mg, 0.1 mmol), $[\text{RhCp}^*\text{Cl}_2]_2$ (1.6 mg, 0.0025 mmol), NaOAc (4.1 mg, 0.05 mmol) and DCE (1 mL). The tube was then sealed, and the mixture was stirred at 50 °C under argon for 6 h. From the resulting mixture, the generation of **4a** was not observed based on TLC detection.



IV. References

- [1] N. Li, X. Zhang and X. Fan, Synthesis of pyrazolidinone fused cinnolines via the cascade reactions of 1-phenylpyrazolidinones with vinylene carbonate, *Tetrahedron Lett.*, 2022, **103**, 153984.
- [2] A. Singh, R. K. Shukla and C. M. R. Volla, Rh(III)-Catalyzed [5+1] annulation of 2-alkenylanilides and 2-alkenylphenols with allenyl acetates, *Chem. Sci.*, 2022, **13**, 2043–2049.
- [3] K.-I. Fujita, Y. Takahashi, M. Owaki, K. Yamamoto and R. Yamaguchi, Synthesis of five-, six-, and seven-membered ring lactams by Cp^{*}Rh complex-catalyzed oxidative *N*-heterocyclization of amino alcohols, *Org. Lett.*, 2004, **6**, 2785–2788.


V. NMR spectra of 3a-3ee





^1H NMR (600 MHz, CDCl_3)





$^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3)







^1H NMR (400 MHz, CDCl_3)





$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3)













¹H NMR (600 MHz, CDCl₃)





¹³C{¹H} NMR (150 MHz, CDCl₃)









¹H NMR (600 MHz, CDCl₃)





¹³C{¹H} NMR (150 MHz, CDCl₃)







^{19}F NMR (565 MHz, CDCl_3)












¹H NMR (600 MHz, CDCl₃)




¹³C{¹H} NMR (100 MHz, CDCl₃)












3i

¹H NMR (600 MHz, CDCl₃)





3i



¹³C{¹H} NMR (150 MHz, CDCl₃)




^{19}F NMR (565 MHz, CDCl_3)













^1H NMR (600 MHz, CDCl_3)




$^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3)




^1H NMR (400 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3)








¹H NMR (400 MHz, CDCl₃)





¹³C{¹H} NMR (100 MHz, CDCl₃)







^1H NMR (400 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3)








¹H NMR (400 MHz, CDCl₃)





¹³C{¹H} NMR (100 MHz, CDCl₃)







¹⁹F NMR (376 MHz, CDCl₃)







¹H NMR (400 MHz, CDCl₃)



¹³C{¹H} NMR (100 MHz, CDCl₃)



-61.278



${}^{19}\text{F}$ NMR (376 MHz, CDCl_3)

0



-50

-100



-150

-200


PPM





^1H NMR (600 MHz, CDCl_3)







$^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3)








¹H NMR (600 MHz, CDCl₃)




¹³C{¹H} NMR (150 MHz, CDCl₃)








^1H NMR (400 MHz, CDCl_3)





$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3)







^1H NMR (400 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3)






¹⁹F NMR (565 MHz, CDCl₃)








^1H NMR (400 MHz, CDCl_3)






$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3)







¹H NMR (600 MHz, CDCl₃)



¹³C{¹H} NMR (150 MHz, CDCl₃)



-62.502



¹⁹F NMR (565 MHz, CDCl₃)



0

-50



-100

-150


-200 PPM





¹H NMR (600 MHz, CDCl_3)





¹³C{¹H } NMR (150 MHz, CDCl_3)








¹H NMR (400 MHz, CDCl_3)





¹³C{¹H } NMR (150 MHz, CDCl_3)







^1H NMR ($400 \text{ MHz}, \text{CDCl}_3$)




$^{13}\text{C}\{\text{H}\}$ NMR ($100 \text{ MHz}, \text{CDCl}_3$)








^1H NMR ($400 \text{ MHz}, \text{CDCl}_3$)





$^{13}\text{C}\{\text{H}\}$ NMR ($100 \text{ MHz}, \text{CDCl}_3$)









^1H NMR (600 MHz, CDCl_3)






$^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3)










$^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3)









^1H NMR (600 MHz, CDCl_3)





3dd

$^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3)







¹H NMR (600 MHz, CDCl₃)





¹³C{¹H} NMR (150 MHz, CDCl₃)







^1H NMR ($400 \text{ MHz, } \text{CDCl}_3$)




$^{13}\text{C}\{\text{H}\}$ NMR ($150 \text{ MHz, } \text{CDCl}_3$)





VI. NMR spectra of 4a-4t








4b
¹H NMR (400 MHz, CDCl_3)





¹³C{¹H} NMR (100 MHz, CDCl_3)








¹H NMR (600 MHz, CDCl_3)




¹³C{¹H} NMR (150 MHz, CDCl_3)






¹H NMR (400 MHz, CDCl₃)






163.569

145.193, 144.080, 140.925, 135.859, 135.395, 134.280, 131.670, 129.606, 128.026, 127.829, 127.615, 127.464, 126.878, 126.734, 126.247, 125.854, 125.696, 121.789, 118.577, 117.451, 76.349, 76.032, 75.714, 64.674, 49.941, 34.313, 33.578, 30.576, 23.352





¹³C{¹H} NMR (100 MHz, CDCl₃)







¹H NMR (400 MHz, CDCl₃)







¹³C{¹H } NMR (100 MHz, CDCl₃)








^{19}F NMR (376 MHz, CDCl_3)









^1H NMR ($400 \text{ MHz, } \text{CDCl}_3$)






$^{13}\text{C}\{^1\text{H}\}$ NMR ($150 \text{ MHz, } \text{CDCl}_3$)









^1H NMR (400 MHz, CDCl_3)




$^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3)







¹H NMR (600 MHz, CDCl_3)



¹³C{¹H} NMR (150 MHz, CDCl_3)



61.204



¹⁹F NMR (565 MHz, CDCl₃)


0

-50


-100

-150

-200 PPM




^1H NMR ($600 \text{ MHz}, \text{CDCl}_3, 55^\circ\text{C}$)





164.225
161.533
159.088

136.542
136.167
132.352
130.776
130.242
129.288
128.672
128.558
128.095
127.954
126.888
126.813
122.728
122.626
109.780
109.534
77.313
77.055
76.737
65.321
50.699
35.269
24.609





$^{13}\text{C}\{\text{H}\}$ NMR ($100 \text{ MHz}, \text{CDCl}_3$)







¹⁹F NMR (565 MHz, CDCl₃, 55 °C)








^1H NMR (400 MHz, CDCl_3)





$^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3)







^1H NMR (400 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3)







^1H NMR (400 MHz, CDCl_3)





144.766
167.316
144.174
136.893
136.445
135.608
132.783
130.689
130.219
129.381
128.934
128.674
128.522
127.944
127.836
126.933
126.723
123.350
122.585
122.000
119.761
77.377
77.060
76.742
65.135
57.717
41.141
24.427
14.323






$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3)










^1H NMR (600 MHz, CDCl_3)





$^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3)












^{19}F NMR (565 MHz, CDCl_3)







^1H NMR (400 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3)








¹H NMR (600 MHz, CDCl₃)




¹³C{¹H} NMR (150 MHz, CDCl₃)





^1H NMR (600 MHz, CDCl_3)





$^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3)







^1H NMR (400 MHz, CDCl_3)




$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3)










¹H NMR (600 MHz, CDCl_3)




¹³C{¹H} NMR (150 MHz, CDCl_3)







¹⁹F NMR (565 MHz, CDCl₃)





VII. NMR spectra of 5a-5d







¹H NMR (600 MHz, CDCl₃)




¹³C{¹H} NMR (150 MHz, CDCl₃)




7.562
7.556
7.481
7.470
7.467
7.405
7.402
7.383
7.380
7.368
7.300
7.297
7.288
7.275
7.263
7.249
7.240
6.983
6.969
6.641
6.614
6.568
5.634
5.628
2.106




^1H NMR (600 MHz, CDCl_3)






161.725
139.054
135.582
132.617
132.223
131.010
128.595
128.345
127.764
127.260
127.067
127.005
116.837
109.390
101.290
77.394
77.077
76.759
67.670
24.107




$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3)








VIII. NMR spectra of 6a-6e





6a
¹H NMR (600 MHz, CDCl₃)





¹³C{¹H} NMR (150 MHz, CDCl₃)







¹H NMR (400 MHz, CDCl₃)





$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3)









¹H NMR (400 MHz, CDCl₃)





¹³C{¹H} NMR (150 MHz, CDCl₃)






$^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3)











IX. NMR spectra of 7a-7e







¹H NMR (600 MHz, CDCl₃)




¹³C{¹H} NMR (100 MHz, CDCl₃)





2.019





¹³C{¹H} NMR (150 MHz, CDCl₃)








¹H NMR (400 MHz, CDCl₃)






¹³C{¹H} NMR (100 MHz, CDCl₃)








^1H NMR (400 MHz, CDCl_3)





$^{13}\text{C}\{\text{H}\}$ NMR (150 MHz, CDCl_3)




X. NMR spectra of 8-9






¹H NMR (600 MHz, CDCl₃)






¹³C{¹H} NMR (100 MHz, CDCl₃)








^1H NMR (600 MHz, CDCl_3)



$^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3)



XI. X-ray crystal structure and data of **3d**




Figure S1 X-ray crystal structure of **3d** with 50% ellipsoid probability

X-ray structure determination. Single crystals suitable for X-ray diffraction were obtained by slow evaporation of the solvent from a dichloromethane solution of **3d**. Crystal data collection and refinement parameters of **3d** are summarized in Table S1. Intensity data were collected at 293 K on a SuperNova Dual diffractometer using mirror-monochromated Cu K α radiation, $\lambda = 1.54184 \text{ \AA}$. The data were corrected for decay, Lorentz, and polarization effects as well as absorption and beam corrections based on the multi-scan technique. Using Olex2, the structure was solved with the SHELXS structure solution program using Direct Methods and refined with the SHELXL refinement package using Least Squares minimisation. Nonhydrogen atoms were refined with anisotropic displacement parameters. The H-atoms were either located or calculated and subsequently treated with a riding model.

Table S1 Crystallographic data and structure refinement results of **3d**

Empirical formula	C ₁₉ H ₁₇ BrN ₂ O
Formula weight	369.25
Temp, K	293(2)
Crystal system	monoclinic
Space group	C2/c
<i>a</i> , Å	31.6641(9)
<i>b</i> , Å	7.1775(2)
<i>c</i> , Å	15.5658(4)
α (°)	90
β (°)	102.601(3)
γ (°)	90
Volume, Å ³	3452.41(17)

Z	8
ρ_{calc} , g cm ⁻³	1.421
λ , Å	1.54184
μ , mm ⁻¹	3.283
No. of data collected	7106
No. of unique data	3291
R_{int}	0.0233
Goodness-of-fit on F^2	1.127
R_1 , wR ₂ ($I > 2\sigma(I)$)	0.0511, 0.1304
R_1 , wR ₂ (all data)	0.0601, 0.1361